Top

Therese Bartholomew Bevers, MD, FAAFP

Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences

About Dr. Bevers

I am a Professor of Clinical Cancer Prevention (CCP) at The University of Texas MD Anderson Cancer Center and the Co-Director of the Clinical Cancer Prevention Research Core. The Research Core provides the infrastructure for the clinical management and recruitment of a number of cancer screening, chemoprevention and biomarker trials. I previously served as the Medical Director of the Cancer Prevention Center (CPC), where I led the development and provided clinical oversight of a comprehensive clinical cancer prevention program for over 29 years. The program provides risk-based cancer screening and personalized cancer risk reduction services to healthy individuals, those at increased risk for cancer, and survivors who may be at risk for secondary cancers. I have overseen the development of screening guidelines for MD Anderson that codify the clinical practice in the CPC.

I have been the PI or Co-PI of numerous studies including Institutional Co-PI for the National Surgical Adjuvant Breast and Bowel Project (NSABP) "Breast Cancer Prevention Trial (BCPT)" and PI for the NSABP "Study of Tamoxifen and Raloxifene (STAR)”, the N01 Consortium “Phase 1b Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with a History of Hormone Receptor-Negative Breast Cancer”. For the STAR Trial, MD Anderson was the largest single site to accrue to the trial. I will oversee the recruitment to the Vanguard Study and provide clinical management of positive results that require further diagnostic evaluation.

Person places their hand over an empty wine glass as someone starts to pour from a wine bottle

Alcohol and breast cancer risk: What to know

Can breastfeeding really lower your breast cancer risk?

Close-up of woman's hand covering a wine class to reject alcohol

5 little-known breast cancer facts

Illustration of disinterested woman pushing food around her plate

10 cancer symptoms women shouldn't ignore

Power blush, bronzer, and eye shadow with makeup brushes

Is talc in makeup safe?

Torso view of towel-wrapped woman applying anti-perspirant

6 breast cancer myths you shouldn’t believe

A man wearing a light blue athletic shirt and white headphones grimaces while holding his elbow

10 cancer symptoms men shouldn't ignore

Close-up of 4 stacked adult and kids' hands, palm up, outlined by a house, with a stone heart in the middle

Adoption and cancer risk: Should you get genetic testing?

Present Title & Affiliation

Primary Appointment

Professor, Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Medical Director, Prevention Outreach Programs, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas

Research Interests

Breast cancer prevention, screening, diagnosis and survivorship

Education & Training

Degree-Granting Education

1987	The University of Texas Health Science Center at San Antonio, San Antonio, Texas, US, MD
1981	Texas Woman's University, Denton, Texas, US, BS in Chemistry, Biology

Postgraduate Training

2014-2014	Clinical Safety & Effectiveness Program, The University of Texas MD Anderson Cancer Center, Houston, Texas
1987-1990	Family Practice Residency, The University of Texas Health Science Center at San Antonio, San Antonio, Texas
1981-1982	Analytical Chemistry, Texas Woman's University, Denton, Texas

Licenses & Certifications

2024	BLS
1990	American Board of Family Practice
1989	DEA
1988	DPS
1988	Texas Medical Board Physician Permit

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2003 - 2009

Assistant Professor, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, 1996 - 2003

Administrative Appointments/Responsibilities

Patient Experience Officer, Cancer Prevention Center, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2017 - Present

Patient Experience Officer, Cancer Prevention Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2017 - Present

Co-Director, Gyn Survivorship Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2017 - Present

Co-Director, GI Survivorship Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2012 - Present

Co-Director, Integrative Health Initiative, Duncan Family Institute for Cancer Prevention and Risk Assessment, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2010 - Present

Co-Director, Clinical Cancer Prevention Research Core, Duncan Family Institute for Cancer Prevention and Risk Assessment, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2010 - Present

Co-Director, Prevention and Survivorship Rotation for Primary Care, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2009 - 2013

Co-Director, Breast Cancer Survivorship Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2007 - Present

Program Leader, Prevention Rotation, Interdisciplinary Breast Cancer Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2001 - 2003

Medical Director, Prevention Outreach Programs, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, 1998 - Present

Medical Director, Professional Education for Prevention and Early Detection, The University of Texas MD Anderson Cancer Center, Houston, Texas, 1998 - 2002

Medical Director, LifeCheq Corporate, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, 1996 - 1998

Co-Director, Primary Care Cancer Elective Rotation, The University of Texas MD Anderson Cancer Center, Houston, Texas, 1996 - 2009

Other Professional Positions

Consultant, Preventive Therapy, Eli Lilly, Inc, New York, New York, 2007 - 2008

Consultant, Preventive Therapy, Merck & Co., Inc, New York, New York, 2005 - 2006

Consultant, Preventive Therapy, Wyeth Pharmaceuticals, New York, New York, 2004 - 2005

Consultant, Preventive Therapy, Discovery International, Chicago, IL, 2000 - 2001

Extramural Institutional Committee Activities

Member, Faculty Appeals Panel, The University of Texas MD Anderson Cancer Center, 2022 - 2024

Chair, Health Index Steering Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present

Member, Screening Alignment (Breast, Colorectal, Lung) Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present

Member, Thoracic Service Line Lung Cancer Screening Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2023

Chair, Tobacco QI Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2022

Member, Internal Advisory Board for the Shared Decision Making Core, The University of Texas MD Anderson Cancer Center, 2021 - Present

Member, Ambulatory Directors Forum, The University of Texas MD Anderson Cancer Center, 2021 - 2025

Committee Member, University of Texas Collaboration on Population Health and Improvement, Cancer Survivorship Workgroup, Clinical Practice Committee, The University of Texas MD Anderson Cancer Center, 2021

Committee Member, University of Texas Collaboration on Population Health and Improvement, Cancer Survivorship Workgroup, The University of Texas MD Anderson Cancer Center, 2021

Member, Ambulatory Leaders Update, The University of Texas MD Anderson Cancer Center, 2020 - 2025

Member, Breast Service Line Leadership Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2025

Member, Breast Service Line Screening Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2025

Member, Ambulatory-CCLT, The University of Texas MD Anderson Cancer Center, 2020 - 2025

Member, Survivorship Operational Priority Team, The University of Texas MD Anderson Cancer Center, 2019 - 2022

Member, Patient Experience Officers Meeting, The University of Texas MD Anderson Cancer Center, 2019 - Present

Member, Faculty Achievement Award Selection Committee (Clinical Research), The University of Texas MD Anderson Cancer Center, 2018

Member, Clinical Cancer Prevention Clinical Research Meeting, The University of Texas MD Anderson Cancer Center, 2018 - Present

Member, ePHDB Work Group, The University of Texas MD Anderson Cancer Center, 2018

Member, Decision Science and Health Economics CPRIT Core Facility Steering Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present

Member, EndHPV Control Advisory Panel (CAP), The University of Texas MD Anderson Cancer Center, 2018 - 2019

Chair, IRG Cancer Survivorship Seed Money Review Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present

Chair, Healthy Living Clinic Steering Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present

Poster Judge, Cancer Survivorship Research Symposium, The University of Texas MD Anderson Cancer Center, 2016

Member, UT Population Health Strategic Plan Steering Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2024

Member, Shared Decision-Making Collaborative Steering Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2020

Survivorship Poster Judge, MD Anderson Trainee Research Day, The University of Texas MD Anderson Cancer Center, 2015

Member, Arceneaux Outstanding Nurse Oncologist Selection Committee, The University of Texas MD Anderson Cancer Center, 2014

Member, Cancer Survivorship Research Advisory Workgroup, The University of Texas MD Anderson Cancer Center, 2014 - Present

Member, Faculty Achievement Award Selection Committee (Patient Care), The University of Texas MD Anderson Cancer Center, 2014 - 2016

Poster Judge, MD Anderson Trainee Research Day, The University of Texas MD Anderson Cancer Center, 2014

Co-Chair, Cancer Survivorship Seed Money Review Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2018

Member, Lung Moonshot-Prevention and Early Detection, The University of Texas MD Anderson Cancer Center, 2013 - 2017

Member, Breast and Ovarian Moonshot, The University of Texas MD Anderson Cancer Center, 2013 - 2019

Member, Search Committee, Division Head of Internal Medicine, The University of Texas MD Anderson Cancer Center, 2013

Member, High-Risk Breast Cancer Cohort and Biorepository Oversight Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present

Member, Center for Energy Balance in Cancer Prevention and Survivorship Advisory Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present

Founding Member, Center for Global Cancer Early Detection, The University of Texas MD Anderson Cancer Center, 2013 - 2015

Member, Clinical Effort Standardization Subcommittee, The University of Texas MD Anderson Cancer Center, 2013 - 2014

Survivorship Poster Judge, MD Anderson Trainee Research Day, The University of Texas MD Anderson Cancer Center, 2012

Member, Patient History Database Data Access Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2019

Member, Faculty Achievement Award Selection Committee (Clinical Research), The University of Texas MD Anderson Cancer Center, 2012

Chair, Clinical Cancer Prevention Clinical Research Meeting, The University of Texas MD Anderson Cancer Center, 2012 - 2017

Member, External Communications Advisory Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2013

Member, Clinical Research Advisory Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2012

Member, Comprehensive Cancer Control-Survivorship Workgroup, The University of Texas MD Anderson Cancer Center, 2011 - 2013

Co-Chair, Duncan Family Institute Clinical Cancer Prevention Research Core Steering Committee, The University of Texas MD Anderson Cancer Center, 2011 - Present

Member, Meaningful Use Steering Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2012

Member, Cancer Survivorship Seed Money Review Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2013

Clinical Sponsor, Patient History Database Project, Phase II, The University of Texas MD Anderson Cancer Center, 2011 - 2013

Member, Comprehensive Cancer Control-Liver Workgroup, The University of Texas MD Anderson Cancer Center, 2011 - 2014

Member, Comprehensive Cancer Control Planning and Implementation Workgroup, The University of Texas MD Anderson Cancer Center, 2011 - 2012

Co-Chair, Integrative Health Working Group, The University of Texas MD Anderson Cancer Center, 2011 - Present

Member, PRS Budget and Finance Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2012

Member, Integrative Cancer Medicine Steering Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2012

Member, PRS Executive Council, The University of Texas MD Anderson Cancer Center, 2010 - 2013

Co-Chair, Comprehensive Cancer Control - Breast Workgroup, The University of Texas MD Anderson Cancer Center, 2010 - 2015

Member, Cancer Survivorship Textbook Workgroup, The University of Texas MD Anderson Cancer Center, 2010 - 2015

Member, Clinical Cancer Prevention Faculty Career Development and Promotion Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2011

Member, Duncan Family Institute Personalized Risk Prediction Program Steering Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2012

Member, Duncan Family Institute Premalignant Genome Atlas Program Steering Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2011

Chair, Cancer Prevention Center Steering Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2025

Member, Comprehensive Cancer Control Data and Prioritization Workgroup, The University of Texas MD Anderson Cancer Center, 2009 - 2011

Alternate Member, Clinical Strategic Advisory Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2012

Member, Duncan Family Institute for Cancer Prevention and Risk Assessment Executive Committee, The University of Texas MD Anderson Cancer Center, 2009 - Present

Member, Cancer Survivorship Education Subcommittee, The University of Texas MD Anderson Cancer Center, 2009 - Present

Member, Faculty Appeals Panel, The University of Texas MD Anderson Cancer Center, 2009 - 2011

Member, Comprehensive Cancer Control Strategic Plan Steering Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2009

Member, Ex Officio, Clinical Cancer Prevention Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2009

Chair, Cancer Survivorship Community Health Professionals Subcommittee, The University of Texas MD Anderson Cancer Center, 2007 - 2016

Member, Cancer Survivorship Passport Working Group, The University of Texas MD Anderson Cancer Center, 2007 - 2008

Member, Extramural Programs US-Middle East Partnership for Breast Cancer Awareness and Research Steering Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2008

Member, Extramural Programs MDACC-DKFZ Steering Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2008

Member, Brand Management Task Force, The University of Texas MD Anderson Cancer Center, 2006 - 2009

Member, Cancer Survivorship Strategic Task Force, The University of Texas MD Anderson Cancer Center, 2006

Member, Multidisciplinary Breast MRI Research Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2009

Member, Cancer Survivorship Steering Committee, The University of Texas MD Anderson Cancer Center, 2006 - Present

Member, Beth Sanders Moore Young Breast Cancer Survivors' Internal Advisory Board, The University of Texas MD Anderson Cancer Center, 2006 - 2008

Member, Breast Program Leadership Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2022

Chair, Cancer Survivorship Models of Care - Tier 1 Working Group, The University of Texas MD Anderson Cancer Center, 2006 - 2007

Member, Cancer Survivorship Clinical Care Workgroup, The University of Texas MD Anderson Cancer Center, 2006 - Present

Co-Chair, Multidisciplinary Clinical Management Conference for Benign Breast Lesions, The University of Texas MD Anderson Cancer Center, 2004 - Present

Member, Evidence Based Cancer Care Advisory Subcommittee, The University of Texas MD Anderson Cancer Center, 2002 - 2004

Member, The University of Texas M.D. Anderson Physician Network Board of Directors, The University of Texas MD Anderson Cancer Center, 2001 - 2006

Co-Chair, Billing Compliance Committee, The University of Texas MD Anderson Cancer Center, 2000 - 2002

Member, Executive Committee of the Faculty Senate, The University of Texas MD Anderson Cancer Center, 1999 - 2003

Co-Chair, Psychosocial, Behavioral, and Health Services Research Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2002

Chair, Faculty Senate Clinical Affairs Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2003

Member, Women Faculty and Administrators Steering Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2000

Member, Office of Protocol Research Scientific Advisory Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2002

Member, Billing Compliance Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2002

Member, Nellie B. Connally Breast Center Operations Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2006

Member, Medical Records Committee, Executive Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 1998 - 2005

Member, Business Development Group, The University of Texas MD Anderson Cancer Center, 1998 - 2000

Member, Quality Management Subcommittee, Executive Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 1997 - 1998

Member, Psychosocial, Behavioral and Health Services Research Committee, The University of Texas MD Anderson Cancer Center, 1997 - 2005

Member, The Learning Center Advisory Committee, The University of Texas MD Anderson Cancer Center, 1996 - 2000

Member, Marketing Council, The University of Texas MD Anderson Cancer Center, 1996 - 1998

Member, Guideline Review Committee, The University of Texas MD Anderson Cancer Center, 1996 - 2001

Member, Faculty Senate Finance Committee, The University of Texas MD Anderson Cancer Center, 1996 - 2003

Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 1996 - 2003

Editorial Activities

Medical Editor, Cancerwise, The University of Texas MD Anderson Cancer Center Blog, 2025 - Present

Section Editor, Current Breast Cancer Reports, 2015 - 2017

Medical Editor, Oncology, The University of Texas MD Anderson Cancer Center, 2015 - 2018

Medical Editor, Focused on Health, The University of Texas MD Anderson Cancer Center, 2008 - 2020

Section Editor, Cancer Prevention, Current Oncology Reports, 2007 - 2011

Section Editor, Journal of the National Comprehensive Cancer Network, 2004 - Present

Editorial Board, Oncology, The University of Texas MD Anderson Cancer Center, 1997 - 2018

Honors & Awards

2024	Top 1% National Recognition for Patient Experience, Press Ganey
2024	Quality Improvement and Patient Safety Award, FY24 MD Anderson Celebration of Faculty Excellence Award Ceremony
2020 - 2021	SBI Honorary Fellow, 2020 SBI/ACR Annual Breast Imaging Symposium
2018	2018 Faculty Excellence Honoree, MD Anderson Cancer Center
2017	2017 Inaugural Clinical Effectiveness Collaborator Award, The University of Texas MD Anderson Cancer Center
2017	2017 President's Recognition for Faculty Excellence in OneConnect Leadership, The University of Texas MD Anderson Cancer Center
2016	2016 Multidisciplinary Breast Program Outstanding Teacher Award, Department of Breast Surgical Oncology, The University of Texas M.D. Anderson Cancer Center
2016	2016 Rodger J. Winn, MD Award for Service and Dedication to the NCCN, National Comprehensive Cancer Network
2016	2016 TWU Distinguished Alumni Award, Texas Woman's University
2016	2016 Texas Business Women’s Award for Outstanding Leadership in Cancer Research and Treatment
2011	2011 Faculty Achievement Award in Cancer Prevention, The University of Texas MD Anderson Cancer Center
2011	2011 Kathryn S. Stream Award for Excellence in Women's Health, The Women's Fund and The Texas Medical Center Women's Health Network
2011	Woman Leading the Way June 2011, Women Faculty Programs, The University of Texas MD Anderson Cancer Center
2006	America's Top Doctors, U.S. News and World Report
2006	2006 The Julie and Ben Rogers Award for Excellence in Prevention, The University of Texas MD Anderson Cancer Center
2000 - 2001	Who's Who in the World
2000 - 2004	Who's Who in America
1998 - 2000	Who's Who in Medicine and Healthcare
1997	Physician of the Day, Seventy-fifth Texas Legislature, January 30,
1987 - 1988	Distinguished Family Practice Resident, The University of Texas Health Science Center at San Antonio
1984 - 1985	Notable Women of Texas

Professional Memberships

American Cancer Society National Breast Cancer Roundtable

2022 - Present

Women's Preventive Services Initiative, Health Resources & Services Administration, US Department of Health and Human Services

2016 - 2017

Breast Cancer Screening Consensus Conference

2016

Southwest Oncology Group

2011 - Present

Alliance for Clinical Trials in Oncology

2011 - Present

Breast Health Collaborative of Texas

2010 - Present

American Cancer Society

2010 - 2016

National Surgical Adjuvant Breast and Bowel Project

2009 - 2015

Avon Foundation

2008 - 2010

National Surgical Adjuvant Breast and Bowel Project

2007 - 2010

National Comprehensive Cancer Network

2005 - Present

American Society of Breast Disease

2005 - Present

American Society of Clinical Oncology

2005 - Present

American Society of Preventive Oncology

2005 - Present

Texas Cancer Plan

2004 - Present

The University of Texas MD Anderson Cancer Center

2004 - Present

National Comprehensive Cancer Network

2003 - Present

Action Plan on Breast and Cervical Cancer for the State of Texas

2003 - Present

American Cancer Society Cancer Action Network

2002 - Present

Association of Governing Boards of Universities and Colleges

2001 - 2007

National Comprehensive Cancer Network

1999

American Medical Association

1997 - Present

Harris County Medical Society

1997 - Present

Texas Medical Association

1996 - Present

Texas Academy of Family Physicians

1987 - Present

American Academy of Family Physicians

1987 - Present

Selected Presentations & Talks

Local Presentations

2019. Second Primary Cancers/Breast Cancer Survivorship Case Discussion. ECHO Telementoring. Conference. MD Anderson Cancer Center. Houston, TX, US.
2017. Understanding Cancer Survivorship. Conference. The University of Houston MD Anderson Cancer Center. Houston, TX, US.
2017. Second Primary Cancers: Review and Case Presentations. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2016. Cancer Prevention Center: An Infrastructure for Clinical Cancer Prevention and Energy Balance Research. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2016. Breast Cancer Survivorship: Transitioning from Disease to Health and Wellness. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2016. Road Map for Cancer Prevention Program Development. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2014. Screening Mammography: Facts and Fiction. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2014. Anastrozole for Prevention of Breast Cancer in High-Risk Postmenopausal Women (IBIS-II): An international, double-blind, randomized placebo-controlled trial. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2013. Roundtable Discussion: Screening for Second Primary Cancers. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2013. Effect of Three Decades of Screening Mammography on Breast Cancer Incidence. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Assessing and Managing High Risk Women. Conference. Houston Breast Imaging Club. Houston, TX, US.
2012. When Patient Autonomy Prevents Treatment. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Cancer Survivorship at MD Anderson. Conference. The University of MD Anderson Cancer Center. Houston, TX, US.
2011. Second Primary Cancers in Lymphoma Survivors. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2011. Second Primary Tumors. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
2010. Cancer Prevention Center: Developing an Infrastructure for Cancer Prevention Research. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2009. Risk-based Breast Cancer Screening. Conference. Women's Hospital of Texas. Houston, TX, US.
2009. Cancer Prevention Center: Research Resources. Conference. M. D. Anderson Cancer Center. Houston, TX, US.
2009. Evidence-based Cancer Screening. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
2009. Controversies in Cancer Screening. Conference. Medscape Oncology. Houston, TX, US.
2008. Breast Cancer Screening for Primary Care. Conference. Texas Academy of Family Physicians Primary Care Summit. Houston, TX, US.
2008. Management of Patients with LCIS and ALH. Conference. The Methodist Hospital. Houston, TX, US.
2008. Panel Member, Management of Patients with LCIS and ALH. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2007. Opportunities for Global Breast Cancer Prevention Initiatives. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
2007. Advances in Cancer Prevention. Conference. The Unversity of Texas M.D. Anderson Cancer Center. Houston, TX, US.
2007. Breast Cancer Prevention: Current Clinical Practice and Future Directions. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
2007. Breast Cancer Prevention: The State of Science. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
2006. STAR Trial: Results and Impact on Clinical Practice. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
2006. Chemoprevention. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
2003. Update on STAR Trial. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
2002. Recruitment and Retention in Prevention Trials. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
2002. Breast Cancer Chemoprevention: Current Clinical Practice and Future Direction. Conference. The University of Texas Health Science Center. Houston, TX, US.
2002. The Role of Ductal Fluid Cellular and Protein Analyses in Breast Cancer Risk Stratification and Biomarker Discovery, Panel Member. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
2002. Screaming about Screening: Does Early Detection Really Make a Difference. Conference. NACCDO/PAN National Conference. Houston, TX, US.
2001. Breast Cancer Chemoprevention. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
2001. Breast Cancer Prevention: Current Clinical Practice and Future Directions. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
2001. Use of Hormones Before and After Breast Cancer, Panel Member. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
2000. Hormonal Management of Women with an Intact Uterus at Increased Risk of Breast Cancer. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
2000. Reducing the Incidence of Breast Cancer in Women with High Risk. Conference. Houston Gynecological and Obstetrics Society. Houston, TX, US.
2000. Breast Cancer Prevention. Conference. Southwest OB/Gyn Group. Houston, TX, US.
2000. STAR Design and M.D. Anderson Cancer Center Logistics. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
2000. Reducing the Incidence of Breast Cancer with Tamoxifen in Women with High Risk. Conference. Discovery International. Houston, TX, US.
1999. Breast Cancer Prevention: Incorporating New Data into Clinical Practice. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
1999. Update of Chemoprevention Trials in Breast Cancer. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
1999. Breast Cancer Prevention. Conference. Discovery International. Houston, TX, US.
1999. Breast Cancer Chemoprevention. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
1999. Breast Cancer Prevention Trial Results. Conference. The University of Texas M. D. Anderson Cancer Center. Houston, TX, US.
1999. Texas Women: Building Health Solutions for the New Millennium. Conference. Department of Health and Human Services Conference. Houston, TX, US.
1999. Breast Cancer Prevention. Conference. Houston Area Dietetic Association. Houston, TX, US.
1997. Cancer Screening Guidelines. Conference. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.

Regional Presentations

2022. 9 Ways to Reduce Your Risk of Cancer. Invited, US.
2018. Translating Cancer Survivorship and Energy Balance Research into Public Health Initiatives. Invited, Texas, US.
2015. Breast Cancer: Risk Assessment, Risk Reduction and Screening. Invited, US.
2015. Breast Cancer: Risk Assessment, Risk Reduction and Screening. Invited. San Antonio, Texas, US.
2015. Cancer Survivorship Clinical Algorithms. Invited. Dallas, Texas, US.
2013. Second Primary Cancers. Invited. Clear Lake, Texas, US.
2012. Cancer Screening: Updates and Controversies. Invited. Abilene, Texas, US.
2012. Assessing and Managing High Risk Women. Invited. Houston, Texas, US.
2011. Breast Cancer for the Primary Care Physician. Invited. Dallas, Texas, US.
2009. Risk-based Breast Cancer Screening. Invited. Houston, Texas, US.
2009. Controversies in Cancer Screening. Invited. Houston, Texas, US.
2008. Breast Cancer Screening for Primary Care. Invited. Houston, Texas, US.
2008. Management of Patients with LCIS and ALH. Invited. Houston, Texas, US.
2006. STAR Panel Session Recruitment. Invited. Denver, Colorado, US.
2004. Breast Cancer and NSAIDs: Exploring the Spectrum of Evidence. Invited. New York, New York, US.
2003. Clinical Trials and the National Lung Screening Trial. Invited. Austin, Texas, US.
2002. Breast Cancer Chemoprevention: Current Clinical Practice and Future Direction. Invited. Houston, Texas, US.
2002. Screaming about Screening: Does Early Detection Really Make a Difference. Invited. Houston, Texas, US.
2000. Reducing the Incidence of Breast Cancer in Women with High Risk. Invited. Houston, Texas, US.
2000. Assessing Breast Cancer Risk and Considering the Prevention Options. Invited. Atlanta, Georgia, US.
2000. Evaluation and Management of Women at High Risk for Breast Cancer. Invited. Baltimore, Maryland, US.
2000. Breast Cancer Prevention. Invited. Houston, Texas, US.
2000. Evaluation and Management of Women at High Risk for Breast Cancer. Invited. New York, New York, US.
2000. Assessing Breast Cancer Risk and Benefits and Risks of Treatment. Invited. Coral Gables, Florida, US.
2000. Reducing the Incidence of Breast Cancer with Tamoxifen in Women with High Risk. Invited. Houston, Texas, US.
1999. Breast Cancer Prevention. Invited. Nacogdoches, Texas, US.
1999. Breast Cancer Prevention. Invited. Waynesville, North Carolina, US.
1999. Texas Women: Building Health Solutions for the New Millennium. Invited. Houston, Texas, US.
1999. Breast Cancer Prevention. Invited. Houston, TX, US.

National Presentations

2025. Cancer prevention - 5 easy steps. OnlineOnly. DoctorPodcasts || Cykiert Files Episode #110, US.
2019. Assessing Cardiorespiratory Fitness in Cancer Survivors: The M.D. Anderson Healthy Heart Program. Conference. Houston, Texas, US.
2019. Imaging and Diagnostic Work-Up for High Risk Patients. Conference. Dallas, Texas, US.
2019. The Healthy Living Weight Loss Program - An Intensive Behavioral Therapy Program for Obesity. Conference, US.
2019. An innovative physical activity intervention in overweight and obese adults using continuous glucose monitor. Conference. San Diego, California, US.
2018. Screening Mammography for Average-Risk Women: The Controversy and NCCN's Position. Invited, US.
2018. The Healthy Living Weight Loss Program - An Intensive Behavioral Therapy Program for Obesity. Conference. Houston, Texas, US.
2018. Breast Cancer, with Updates from the 2017 SABCS. Invited, US.
2018. Cancer Screening Principles: Current Practice and Future Perspectives. Invited. Houston, Texas, US.
2018. The Healthy Living Weight Loss Program - An Intensive Behavioral Theraphy Program for Obesity. Conference, US.
2018. Risk for Second Primary Malignancies among Breast Cancer Patients. Conference. Seattle, Washington, US.
2018. Breast Cancer Risk Counseling. Conference. Houston, Texas, US.
2017. Impact of a Patient Decision Aid on Smokers' Knowledge of Lung Cancer Screening Harms and Benefits: Project Inform, a Randomized Controlled Trial. Conference. Pittsburgh, Pennsylvania, US.
2017. Assessing Cardiorespiratory Fitness in Early Stage Breast Cancer: The M.D. Anderson Healthy Heart Program. Conference. Denver, Colorado, US.
2017. Adherence to physical activity guidelines in a cancer prevention and control setting: the impact of body mass index. Conference. Austin, Texas, US.
2017. Breast Cancer Risk Reduction Strategies. Invited, US.
2017. Breast Cancer Risk Reduction Strategies. Invited. Chicago, Illinois, US.
2017. Patient-Centered Physical Activity Assessment and Intervention Process. Conference, US.
2017. A Patient Centered Intervention for Adaptation of Cancer Risk Reduction Guidelines in Breast Cancer Survivors. Conference. Houston, Texas, US.
2016. Identifying and Addressing Nutrition and Physical Activity Needs for Cancer Risk Reduction in a Comprehensive Cancer Center. Conference. Bethesda, Maryland, US.
2016. Physical Activity Algorithm in a Comprehensive Cancer Center. Conference. Boston, Massachusetts, US.
2016. Use and adherence to breast cancer risk-reduction agents: A population-based study. Poster Session: Cancer Prevention, Genetics, and Epidemiology. Board #381. Conference, US.
2016. Standardizing Energy Balance Clinical Practice, Education, Communication and Research. Conference. Houston, Texas, US.
2016. Multidisciplinary Approach to Indeterminate Breast Lesions. Invited. Las Vegas, Nevada, US.
2016. Management of Postmenopausal Women at Increased Risk for Breast Cancer. Conference. Las Vegas, Nevada, US.
2016. Controversies in Breast Cancer Screening Strategies. Invited. Hollywood, Florida, US.
2016. Undiagnosed Breast Clinic: Management of Presenting Breast Abnormalities. Invited, US.
2015. Results from NRG oncology/NSABP protocol DMP-1: Women's decision-making. Conference, US.
2015. Moderator, MD Anderson Survivorship Clinics. Invited. Houston, Texas, US.
2015. Identifying and Addressing Nutrition and Physical Activity needs for Cancer Risk Reduction in a Comprehensive Cancer Center. Conference. Boston, Massachusetts, US.
2015. Integrative Health Services in a Breast Survivorship Clinic. Conference. Houston, Texas, US.
2015. NCCN 2015 Webinar Series: Breast Cancer with Updates from the 2014 SABCS, Breast Cancer Risk Reduction Strategies. Invited, US.
2015. The Role of a Exercise Physiology Technologist in a Cancer Prevention Center. Conference. Houston, Texas, US.
2015. Decision-making in breast cancer risk reduction: Results from a nested qualitative study from NRG Oncology/NSABP protocol DMP-1. Conference. Houston, Texas, US.
2015. Pilot Project for Improving Coordination of Care for Breast Cancer Survivor in the Cancer Prevention Center. Conference. Houston, Texas, US.
2015. Pilot Project for Improving Coordination of Care for Breast Cancer Survivor in the Cancer Prevention Center. Conference. Houston, Texas, US.
2014. Breast Cancer High Risk Workshop: Case-Based Approach. Invited. Orlando, Florida, US.
2014. Developing an Effective Breast Survivorship Program in Academia. Invited. Chicago, Illinois, US.
2014. Standardizing Energy Balance Clinical Practice, Education Communication and Research. Conference. Houston, Texas, US.
2014. Introduction of Physical Activity Assessment and Follow-up in a Cancer Prevention Center. Conference. Houston, Texas, US.
2014. Integrative Health Services in the Cancer Prevention Center. Conference. San Antonio, Texas, US.
2014. Integrative Health Services in the Cancer Prevention Center. Conference. Houston, Texas, US.
2014. Integrative Health Pilot Phase II - Improving Linkage to Breast Cancer Survivorship - Specific Services. Conference. Houston, Texas, US.
2014. A Program Evaluation of Best Practice Methods to Assess Integrated Health Needs for Breast Cancer Survivors. Conference. Boston, Massachusetts, US.
2014. Controversies in Cancer Screening. Invited. Chicago, Illinois, US.
2014. Introduction of Physical Activity Assessment and Follow-Up in an Cancer Prevention Center. Conference. Orlando, Florida, US.
2014. Risk of breast cancer in women observed after core biopsy diagnosis of atypical ductal hyperplasia. Conference. Phoenix, Arizona, US.
2014. A Bright Idea - Discovering consistent Energy Balance Messages throughout the Cancer Continuum. Conference. Houston, Texas, US.
2014. Prevalence of breast stem cells in high risk benign breast lesions and association with breast feeding. Conference, US.
2013. Supplemental Ultrasound (US) Screening in Patients with a History of Lobular Neoplasia (LN). Conference. Chicago, Illinois, US.
2013. Improving Survivor's quality of Care Through Self-Reported Satisfaction Data. Conference. San Antonio, Texas, US.
2013. Supplemental Ultrasound (US) Screening in Patients with a History of Lobular Neoplasia (LN). Conference. Chicago, Illinois, US.
2013. Do Online Risk Assessment Tools Increase Information Seeking Intentions? An Evaluation of Cancer Risk Check. Conference. Washington, DC, US.
2013. Risk-based Cancer Prevention and Screening. Invited. Houston, Texas, US.
2013. Integrative Health Breast Cancer Survivorship Services Pilot at The University of Texas MD Anderson Cancer Center. Conference. Vancouver, Washington, US.
2013. Pilot Project for Improving Coordination of Care for Breast Cancer Survivors in the Cancer Prevention Center. Conference. Houston, Texas, US.
2013. Needs Identification Process of the Breast Cancer Survivorship Services Pilot. Conference. Vancouver, Washington, US.
2013. Needs Identification Process of the Breast Cancer Survivorship Services Pilot. Conference. Houston, Texas, US.
2013. Integrative Health Breast Cancer Survivorship Services Pilot. Conference. Houston, Texas, US.
2013. Integrative Health Program at MD Anderson's Cancer Prevention Center. Conference. Vancouver, Washington, US.
2013. User Perceptions and Reactions to Online Cancer Risk Assessment Tools: A Process Evaluation of MD Anderson's Cancer Risk Check. Conference. Seattle, Washington, US.
2013. Integrative Health Breast Cancer Survivorship Services Pilot. Conference. Seattle, Washington, US.
2013. Integrative Health Program at MD Anderson's Cancer Prevention Center. Conference. Seattle, Washington, US.
2013. Needs Identification Process of the Breast Cancer Survivorship Services Pilot. Conference. Seattle, Washington, US.
2013. Pharmacologic Risk Reduction Strategies for Women at Increased Risk of Breast Cancer. Invited, US.
2013. Screening for Breast Cancer at MD Anderson. Invited. Houston, Texas, US.
2013. Integrative Health Program at MD Anderson's Cancer Prevention Center. Conference. Houston, Texas, US.
2013. Pharmacologic Risk Reduction Strategies for High Risk Women. Invited. Hollywood, Florida, US.
2013. Are Online Cancer Risk Assessment Tools More Effective Than Traditional Approaches? Examining the Effects of Cancer Risk Check. Conference. Memphis, Tennessee, US.
2013. Management of High Risk Patients. Invited. Amelia Island, Florida, US.
2013. The evaluation of breast cancer chemoprevention uptake in a high-risk cohort. Conference, US.
2013. Neural Correlates of Reduced Sexual Desire in Breast Cancer Survivors: An fMRI Pilot Study. Conference. Houston, Texas, US.
2012. Breast Cancer Screening and Diagnosis. Invited, US.
2012. Patients' Reactions to a Decision Aid about Lung Cancer Screening with Low-dose Spiral Computed Tomography. Conference. Austin, Texas, US.
2012. Acceptability of a patient decision aid for lung cancer screening. Conference. Austin, Texas, US.
2012. Cancer Screening: Updates and Controversies. Invited. Phoenix, Arizona, US.
2012. An integrated professional oncology curriculum for Texas primary care professionals: improving care and enhancing quality of life for breast, colon and prostate cancer survivors. Conference. Austin, Texas, US.
2012. Ovarian cancer screening with CA 125 and selective use of ultrasound: sonographic findings. Conference, US.
2012. Gail Model for Breast Cancer Risk Assessment. Conference. Dallas, Texas, US.
2012. Pharmacologic Risk Reduction Strategies for High Risk Women. Invited. Dallas, Texas, US.
2012. Impact of past chemotherapy on emotional processing: an fMRI study in breast cancer survivors. Conference, US.
2012. “Adenoma detection rates” - How far can we push the envelope?. Conference, US.
2012. Biomarker effects of an oral green tea extract, Polyphenon E, in women with a history of hormone receptor-negative breast cancer. Conference. Anaheim, California, US.
2012. Biomarker effects of an oral green tea extract, Polyphenon E, in women with a history of hormone receptor-negative breast cancer. Conference. Anaheim, California, US.
2011. Risk Profiling Using HPV Genotyping in Women with Mildly Abnormal Pap Results. Conference. Baltimore, Maryland, US.
2011. Comparative Effectiveness of Therapies for Reducing the Risk of Primary Breast Cancer: Guidance for Shared Decision Making. Invited. Fort Lauderdale, Florida, US.
2011. An integrated professional oncology curriculum for primary care professionals: improving care and enhancing quality of life for breast, colon and prostate cancer survivors. Conference. Las Vegas, Nevada, US.
2011. An integrated professional oncology curriculum for primary care professionals: improving care and enhancing quality of life for breast, colon and prostate cancer survivors. Conference. San Antonio, Texas, US.
2011. A cancer survivorship management rotation for primary care trainees. Conference, US.
2011. Development and implementation of a video-based decision aid for lung cancer screening. Conference, Texas, US.
2011. Quality of life in a chemoprevention trial of an oral green tea extract among women with hormone receptor-negative breast cancer. Conference, US.
2010. The willingness to accept chemoprevention strategies by women at increased risk of breast cancer. Conference, US.
2010. Cancer Prevention Clinical Trials and Services. Conference. Houston, Texas, US.
2010. Cancer risk check offers a personalized feedback based on individual cancer risk. Conference, US.
2010. An integrated professional oncology curriculum for Texas primary care professionals: Improving care and enhancing quality of life for breast, colon and prostate cancer survivors. Conference, Texas, US.
2009. Co-screening women 30 years of age and older using hybrid capture® 2 HPV DNA testing and pap cytology: 2-year experience in a cancer prevention center. Conference. Denver, Colorado, US.
2007. HPV DNA co-screening with pap cytology in women age 30 and older in a Cancer Prevention Center. Conference. Houston, Texas, US.
2007. Breast Cancer Risk Reduction. Invited. Hollywood, Florida, US.
2007. Relative effects of tamoxifen, raloxifene, and estrogen therapy on cognition: results from the Women's Health Initiative Study of Cognitive Aging (WHISCA) and the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) clinical trials. Conference, US.
2004. The Future of Cancer Prevention and Early Detection. Invited. Austin, Texas, US.
2004. BRCA 1 & 2: Risk Reduction Strategies. Invited. Steamboat Springs, Colorado, US.
2003. Breast Cancer Screening and Diagnosis Procedures. Invited. Houston, Texas, US.
2003. Breast Cancer Risk Assessment, Screening and Prevention. Invited. New Orleans, Louisiana, US.
2003. Breast Cancer Chemoprevention. Invited. New Orleans, Louisiana, US.
2003. Breast Cancer Prevention: Current Clinical Practice and Future Direction. Invited. Snowmass, Colorado, US.
2003. Breast Cancer Prevention: Current Clinical Practice and Future Direction. Invited. El Paso, Texas, US.
2002. Breast Cancer Prevention: Current Clinical Practice and Future Direction. Invited. Houston, Texas, US.
2002. Breast Cancer Chemoprevention. Invited. Detroit, Michigan, US.
2002. Panel Member, Breast Cancer Prevention: Current Clinical Practice and Future Direction, Assessing Breast Cancer Risk and Considering the Prevention Options. Invited. Ft Worth, Texas, US.
2002. Breast Cancer Prevention: Current Clinical Practice and Future Direction. Invited. Steamboat Springs, Colorado, US.
2001. Breast Cancer Chemoprevention: Current Clinical Practice and Future Directions. Invited. Houston, Texas, US.
2000. Panel Member, Hormone Replacement Therapy, Tamoxifen and Raloxifene: Sorting through the Data and Determining What Therapy is Best for Whom, STAR Scientific Session. Invited. Pittsburgh, Pennsylvania, US.
2000. Breast Cancer Prevention: Incorporating New Data into Clinical Practice. Invited. Houston, Texas, US.
2000. Cancer Prevention: Current Practice and Future Directions. Invited. Houston, Texas, US.
2000. STAR Principal Investigator Panel Session. Invited. New Orleans, Louisiana, US.
1999. Breast Cancer Prevention. Invited. Houston, Texas, US.
1999. Evidence-based Cancer Screening. Invited. Orlando, Florida, US.
1999. Breast Cancer Prevention. Invited. Wichita, Kansas, US.
1999. Breast Cancer Screening and Diagnostic Guidelines. Invited. Breckenridge, Colorado, US.
1999. Evidence-based Cancer Screening. Invited. Breckenridge, Colorado, US.
1998. Breast Cancer Screening Guidelines. Invited. Ft. Lauderdale, Florida, US.
1997. Evidence-based Cancer Screening Workshop. Invited. Houston, Texas, US.

International Presentations

2025. Multidisciplinary Approach to Management of High-Risk Breast Lesions. Invited. Project NOTRE (Indonesia Breast Cancer ECHO). Jakarta, ID.
2025. Why are more women under 50 getting cancer?. OnlineOnly. Cancerwise, US.
2017. Impact of a Patient Decision Aid on Smokers' Knowledge of Lung Cancer Screening Harms and Benefits: Project Inform, a Randomized Controlled Trial. Conference. 39th Annual Meeting of the Society for Medical Decision Making. Pittsburgh, US.
2016. Smoking history and eligibility for lung cancer screening: How close is close enough?. Conference. 38th Annual North American Meeting of the Society for Medical Decision Making. Vancouver, CA.
2016. Identifying and Addressing Nutrition and Physical Activity Needs for Cancer Risk Reduction in a Comprehensive Cancer Center. Conference. International Cancer Education Conference (ICEC). Bethesda, US.
2016. Use and adherence to breast cancer risk-reduction agents: A population-based study. Poster Session: Cancer Prevention, Genetics, and Epidemiology. Board #381. Conference. 2016 ASCO Annual Meeting (#1558), US.
2015. Identifying and Addressing Nutrition and Physical Activity needs for Cancer Risk Reduction in a Comprehensive Cancer Center. Conference. SIO 12th International Conference. Boston, US.
2015. Casting uncertainty in LCIS recommendations through two patient narratives. Conference. Aarhus 2015 - 8th meeting of Ca-Pri, DK.
2014. Breast Cancer High Risk Workshop: Case-Based Approach. Invited. 18th Senologic International Society-American Society of Breast Disease World Congress on Breast Healthcare. Orlando, US.
2014. Standardizing Energy Balance Clinical Practice, Education Communication and Research. Conference. SIO 11th International Conference. Houston, US.
2014. A Program Evaluation of Best Practice Methods to Assess Integrated Health Needs for Breast Cancer Survivors. Conference. ASCO Quality Symposium. Boston, US.
2014. Integrative Health Pilot Phase II - Improving Linkage to Breast Cancer Survivorship - Specific Services. Conference. SIO 11th International Conference. Houston, US.
2014. Introduction of Physical Activity Assessment and Follow-up in a Cancer Prevention Center. Conference. SIO 11th International Conference. Houston, US.
2014. Controversies in Cancer Screening. Invited. American Society of Clinical Oncology, Association of Physician Assistants in Oncology and Oncology Nursing Society. Chicago, US.
2013. Integrative Health Program at MD Anderson's Cancer Prevention Center. Conference. International Conference of the Society for Integrative Oncology (SIO). Vancouver, US.
2013. Integrative Health Breast Cancer Survivorship Services Pilot at The University of Texas MD Anderson Cancer Center. Conference. Society for Integrative Oncology. Vancouver, US.
2013. Needs Identification Process of the Breast Cancer Survivorship Services Pilot. Conference. Society for Integrative Oncology. Vancouver, US.
2013. User Perceptions and Reactions to Online Cancer Risk Assessment Tools: A Process Evaluation of MD Anderson's Cancer Risk Check. Conference. International Cancer Education Conference. Seattle, US.
2013. Case-based Approach to Personalized Risk Assessment and Management. Invited. Canadian Breast Cancer Symposium. Toronto, CA.
2013. Patients' Reactions to a Decision Aid About Lung Cancer Screening with Low-dose Spiral Computed Tomography. Conference. 2013 International Shared Decision Making Conference. Lima, PE.
2013. Patients' reactions to a decision aid about lung cancer screening with low-dose spiral computed tomography: an uncontrolled trial. Conference. International Shared Decision Making Conference, Lima, Peru (#1564), PE.
2011. The Results of a Breast Cancer Screening Camp at A District Level in Rural India. Conference. 3rd Annual European Forum for Evidence Based Prevention. Krems an der Donau, AT.
2010. The willingness to accept chemoprevention strategies by women at increased risk of breast cancer. Conference. AACR International Conference on Frontiers in Cancer Prevention Research (#PR-08), US.

Formal Peers

2015. Screening Mammography: Facts and Faction. Invited. Houston, TX, US.
2014. Breast Cancer Survivorship: Transitioning from Disease to Health and Wellness. Invited. Garden City, Long Island, NY, US.
2012. Screening and Follow-up of Your Breast Cancer Patients. Invited. Los Angeles, CA, US.
2011. Cancer Screening at M D Anderson--An update. Invited. Beaumont, TX, US.
2011. Risk-based Breast Cancer Screening. Invited. Houston, TX, US.
2011. Cancer Survivorship Essentials: Coordinating Care After Treatment. Invited. Olympia, WA, US.
2009. Prevention of Cancer in Women: Breast cancer screening and prevention. Invited. Johnson City, TN, US.
2006. Breast Cancer Prevention: Research to Clinical Practice. Invited. Lufkin, TX, US.
2005. Breast Cancer Prevention: Current Clinical Practice and Future Direction. Invited. Chicago, IL, US.
2004. Cancer Prevention and You. Invited. Augusta, GA, US.
2003. Breast Cancer Prevention: Current Clinical Practice and Future Direction. Invited. Houston, TX, US.
2003. Breast Cancer Screening and Prevention,. Invited. Racine, WI, US.
2003. Breast Cancer Prevention: Current Clinical Practice and Future Direction. Invited. Brazosport, TX, US.
2003. Breast Cancer Prevention: Current Clinical Practice and Future Direction. Invited. Beaumont, TX, US.
2003. Breast Cancer Prevention: Current Clinical Practice and Future Direction. Invited. Houston, TX, US.
2003. Breast Cancer Prevention: Current Clinical Practice and Future Direction. Invited. Laredo, TX, US.
2003. Breast Cancer Prevention: Current Clinical Practice and Future Direction. Invited. Pittsburgh, PA, US.
2002. Breast Cancer Prevention: Current Clinical Practice and Future Direction. Invited. Mexico City,, NM, MX.
2002. Breast Cancer Prevention: Current Clinical Practice and Future Direction. Invited. Shreveport, LA, US.
2002. Cancer Prevention Current Clinical Pratice and Future Direction. Invited. Sherman, TX, US.
2002. Breast Cancer Prevention: Current Clinical Practice and Future Direction. Invited. Tyler, TX, US.
2001. Breast Cancer Chemoprevention. Invited. Galveston, TX, US.
2000. Emerging Strategies in Breast Cancer Prevention. Invited. Beaumont, TX, US.
2000. Reducing the Incidence of Breast Cancer in Women with High Risk. Invited. Macon, GA, US.
2000. Breast Cancer: Risk Reduction and Screening. Invited. Orlando, FL, US.
2000. Breast Cancer Prevention: Incorporating New Data into Clinical Practice. Invited. Santa Rosa, CA, US.
2000. Breast Cancer Prevention: Incorporating New Data into Clinical Practice,. Invited. Concord, CA, US.
2000. Breast Cancer Prevention: Incorporating New Data into Clinical Practice,. Invited. Honolulu, HI, US.
2000. Breast Cancer Prevention: Incorporating New Data into Clinical Practice. Invited. Fargo, ND, US.
1999. Breast Cancer Prevention: Incorporating New Data into Clinical Practice. Invited. Philadelphia, PA, US.
1999. Chemoprevention of Breast Cancer. Invited. Abiliene, TX, US.
1999. Breast Cancer Prevention: Incorporating New Data into Clinical Practice. Invited. Birmingham, AL, US.
1999. Reducing the Incidence of Breast Cancer in Women with High Risk,. Invited. Houston, TX, US.
1999. Breast Cancer Prevention: Incorporating New Data into Clinical Practice. Invited. Tupelo, MS, US.
1999. Breast Cancer Prevention. Invited. Lufkin, TX, US.
1999. Results of the Breast Cancer Prevention Trial and Breast Cancer Risk Reduction. Invited. Houston, TX, US.
1998. Breast Cancer Prevention. Invited. Houston, TX, US.
1998. Evidence-based Cancer Screening. Invited. Alexandria, LA, US.
1998. Evidence-based Cancer Screening. Invited. Houston, TX, US.
1997. Evidence-based Cancer Screening. Invited. Lufkin,, TX, US.
1997. Cancer Prevention. Invited. Wharton, TX, US.
1997. Cancer Prevention: A Clinician's Approach. Invited. Houston, TX, US.
1997. Cancer Prevention: The Clinician's Approach. Invited. West Palm Beach, FL, US.

Less

Grant & Contract Support

Date:	2022 - 2029
Title:	Investigation of Melody®, a Lab Developed Test For Breast Cancer, As A Supplement Tool for Women with Dense Breast Tissue
Funding Source:	Namida Lab, Inc
Role:	PI
ID:	2022-0073

Date:	2020 - 2021
Title:	2020-0724: DROPLET-BRC study
Funding Source:	Preferred Medicine, Inc
Role:	Collaborator

Date:	2020 - 2027
Title:	A Randomized Phase II Window-of Opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions
Funding Source:	Incyte Corporation/Johns Hopkins University
Role:	Co-PI
ID:	NCT02928978/ TBCRC042

Date:	2019 - 2025
Title:	Analysis by EarlyGuard of Serum miRNA from Women Referred for additional testing
Funding Source:	Toray International America, Inc
Role:	PI
ID:	PA19-0033

Date:	2017 - 2022
Title:	Breast Cancer Screening: Priorities and Attitudes of Diverse Women Under 50
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	1K99 MD011485-01A1

Date:	2017 - 2019
Title:	A Pilot Study of the Use of Serum miRNA for the Risk Stratification of Women with Screening Mammograms Suspicious for Breast Cancer
Funding Source:	Toray International America, Inc
Role:	PI

Date:	2016 - 2019
Title:	A Prospective Validation Study of a Rapid Point-of-Care Breath Test For Breast Cancer (2016-0480)
Funding Source:	Menssana Research Inc/NIH
Role:	PI

Date:	2015 - 2019
Title:	Improving Service Delivery to Cancer Survivors in Primary Care Settings
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Advisor
ID:	PP160027

Date:	2015 - 2016
Title:	Lung Moonshot, Moon Shots Lung Early Detection Project
Funding Source:	MDACC
Role:	Collaborator

Date:	2015 - 2016
Title:	Breast / Ovarian Moonshot Prevention Project C
Funding Source:	MDACC
Role:	Co-PI

Date:	2015 - 2021
Title:	Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology after 12 months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention versus Placebo Control in Premenopausal Women (Alliance 211102)
Funding Source:	Alliance
Role:	PI
ID:	1UG1CA189823-03

Date:	2014 - 2017
Title:	Promoting Informed Decisions about Lung Cancer Screening
Funding Source:	Patient Centered Outcomes Research Institute
Role:	Co-PI
ID:	PA14-0072

Date:	2013 - 2018
Title:	A Randomized Phase II Trial of Low Dose Aspirin versus Placebo in High-Risk Individuals with CT Screen Detected Subsolid Lung Nodules (2013-0732)
Funding Source:	NCI-DCP
Role:	PI
ID:	HHSN261201200034I

Date:	2013 - 2017
Title:	Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction
Funding Source:	NIH/NCI
Role:	Principal Investigator-MDACC
ID:	7R01CA140245-06

Date:	2013 - 2018
Title:	Patient Centered Outcome Research in the Elderly
Funding Source:	The University of Texas Medical Branch at Galveston
Role:	Co-PI
ID:	1R24HS022134-01

Date:	2013 - 2013
Title:	Blood Test for Breast Cancer Associated Auto Antibodies
Funding Source:	Eventus Diagnostics, Inc
Role:	Principal Investigator-MDACC
ID:	LAB09-0756

Date:	2012 - 2016
Title:	A Randomized Double-Blind Placebo Controlled Biomarker Modulation Study of High Dose Vitamin D in Premenopausal Women at High Risk for Breast Cancer Phase IIB
Funding Source:	SWOG
Role:	Principal Investigator-MDACC
ID:	U10 CA105409

Date:	2012 - 2015
Title:	Vitamin D and Breast Cancer Biomarkers
Funding Source:	Alliance
Role:	Principal Investigator-MDACC
ID:	NCT01224678

Date:	2012 - 2013
Title:	P5 Treatment Protocol
Funding Source:	NSABP
Role:	Principal Investigator-MDACC
ID:	U10 CA373377-25

Date:	2012 - 2014
Title:	NSABP- Community Clinical Oncology Program Research Base
Funding Source:	NSABP
Role:	PI
ID:	2 U10 CA037377 01

Date:	2012 - 2014
Title:	Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Funding Source:	NSABP
Role:	Principal Investigator-MDACC
ID:	5U10 CA037377 22

Date:	2011 - 2011
Title:	The Use of Simulated Whole Saliva as a Diagnostic Test for the Detection of Breast Cancer
Funding Source:	University of Texas Dental Branch-Houston
Role:	Collaborator

Date:	2011 - 2012
Title:	The Use of Saliva as Diagnostic Fluid for the Detection of Breast Cancer in Women
Funding Source:	Assurance Biosciences, Incorporated
Role:	PI

Date:	2010 - 2013
Title:	An Integrated Professional Oncology Curriculum for Texas Primary Care Professionals: Improving Care and Enhancing Quality of Life for Breast, Colon and Prostate Cancer Survivors
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	10-05-01-PP100157

Date:	2010 - 2015
Title:	Statistical Methods for Breast Cancer Prevention and Treatment Studies and Therapeutic Response
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	5-R01-CA079466 13

Date:	2010 - 2013
Title:	Using Multimedia Approaches to Communicate Probabilities in Patient Decision Aids for Low-Literacy Populations: Randomized Trial
Funding Source:	Foundation for Informed Medical Decision Making-(FIMDM)
Role:	CO-I
ID:	FIMDM Research Grant 0169-1

Date:	2009 - 2010
Title:	The Use of Stimulated Whole Saliva as a Diagnostic Test for the Detection of Breast Cancer in Women
Funding Source:	Susan G. Komen Breast Cancer Foundation
Role:	Co-PI
ID:	000 6744(A) 01

Date:	2006 - 2012
Title:	Phase IB Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women With a History of Hormone Receptor-Negative Breast Cancer
Funding Source:	NIH/NCI
Role:	Principal Investigator-MDACC
ID:	N01 CN-035159 07

Date:	2001 - 2008
Title:	Effects of Selective Estrogen Receptor Modulators on Cognitive Aging: Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR)
Funding Source:	NSABP
Role:	Principal Investigator-MDACC

Date:	2000 - 2005
Title:	STAR Community Outreach Coordinator
Funding Source:	NSABP
Role:	PI

Date:	1999 - 2010
Title:	Early Detection of Epithelial Ovarian Cancer
Funding Source:	National Cancer Institute-DHHS-NIH-P50
Role:	Collaborator
ID:	5 P50 CA083639 08(PP-1)

Title:	CASCADE-LUNG: Cancer Screening Assay using DELFI; A Clinical Validation Study in Lung
Funding Source:	Delfi Diagnostics, Inc
Role:	PI
ID:	2022-0833

Title:	DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study
Funding Source:	Delfi Diagnostics, Inc
Role:	PI
ID:	2022-0956

Selected Publications

Peer-Reviewed Articles

Middleton LP, Perkins GH, Whitman GJ, Mouabbi JA, Bevers TB, Yi M, Hunt KK. Immediate and ipsilateral recurrence rates and treatment recommendations for patients with pleomorphic and florid lobular carcinoma in situ. Breast Cancer Res Treat 213(2):225-235, 2025. e-Pub 2025. PMID: 40637967.
Zaveri, S, Sun, SX, Zaghloul, T, Bevers, TB, Albarracin, C, Patel, MM, Bedrosian, I. Trends in Atypical Ductal Hyperplasia Diagnosis and Upgrade. Annals of surgical oncology 32(5):3244-3251, 2025. e-Pub 2025. PMID: 39875718.
Akiyama H, Barke L, Bevers TB, Rose SJ, Hu JJ, McAleese KA, Campos SS, Kondou S, Atsumi J, Soriano TF. Performance of a Logistic Regression Model Using Paired miRNAs to Stratify Abnormal Mammograms for Benign Breast Lesions. Cancer Med 14(8):e70767, 2025. e-Pub 2025. PMID: 40231553.
Zaveri S, Sun SX, Zaghloul T, Bevers TB, Albarracin CT, Patel M, Bedrosian I. ASO Visual Abstract. Ann Surg Oncol 32(5):3339-3340, 2025. e-Pub 2025. PMID: 40080363.
Liao Y, Brannon GE, Rethorst CD, Baum M, Bevers TB, Schembre SM, Basen-Engquist KM. Using Continuous Glucose Monitoring as a Biological Feedback Strategy to Motivate Physical Activity in Cancer Survivors: A Mixed-Methods Pilot Study. Cancer Control 32:10732748251359406, 2025. e-Pub 2025. PMID: 40719638.
Whisenant MS, Jones JT, Gonzalez AO, Bevers TB, Brassil K, Ponce DA, Kamat S, Solis E, Maliackal A, Warlick H, Walters A, Denham C, Williams LA. The symptom burden of women with a known risk of breast cancer receiving risk reducing medication. Cancer Treat Res Commun 43:100784, 2025. e-Pub 2025. PMID: 40252396.
Phillips M, Bevers TB, Larsen LH, Pappas N, Pathak S. BREATH TEST TO DETECT WOMEN AT LOW RISK FOR BREAST CANCER: POTENTIAL CLINICAL AND ECONOMIC BENEFITS. medRxiv, 2024. e-Pub 2024. PMID: 39417144.
Phillips M, Bevers T, Larsen L, Pappas N, Pathak S. Rapid point-of-care breath test predicts breast cancer and abnormal mammograms in symptomatic women. J Breath Res, 2024. e-Pub 2024. PMID: 39265580.
MCGUINNESS JE, BEVER TB, GOODMAN GE. Effects of vitamin D supplementation on a deep learning-based mammographic evaluation in SWOG S0812. JNCI Cancer Spectrum 8(4), 2024. e-Pub 2024. PMID: 38814817.
Everidge, S, Sun, J, Teshome, M, Tamirisa, N, Sun, SX, Adesoye, T, Nia, ES, Bevers, TB, Bedrosian, I, Patel, MM, Singh, P. Lobular Neoplasia Diagnosed by MRI-Guided Breast Biopsy. Annals of surgical oncology 31(4):2276-2277, 2024. e-Pub 2024. PMID: 38117388.
Han C, Lu K, Bevers TB. Normal Risk Ovarian Screening Study. Journal of Clinical Oncology 42(10):102-1109, 2024. e-Pub 2024. PMID: 38194613.
Davaro, E, Tinnirello, AA, Bevers, TB, Milbourne, A, Bassett Jr, R, Stewart, J, Guo, M. Efficacy of Cobas HPV testing for predicting grade 2+ cervical intraepithelial neoplasia in a cancer prevention center and a gynecologic oncology clinic. Cancer Cytopathology 132(3):152-160, 2023. e-Pub 2023. PMID: 38054363.
Blakeslee, SB, Gunn, CM, Parker, PA, Fagerlin, A, Battaglia, TA, Bevers, TB, Bandos, H, McCaskill-Stevens, W, Kennedy, JW, Holmberg, C. Talking numbers. BMJ open 13(11), 2023. e-Pub 2023. PMID: 37984961.
Bevers TB, Niell BL, Baker JL, Bennett DL, Bonaccio E, Camp MS, Chikarmane S, Conant EF, Eghtedari M, Flanagan MR, Hawley J, Helvie M, Hodgkiss L, Hoyt TL, Ivanovich J, Jochelson MS, Kulkarni S, Lancaster RB, Mauer C, Maxwell J, Patel BK, Pearlmen M, Philpotts L, Plecha D, Plichta JK, Shakeri S, Smith ML, Streibert CL, Strigel RM, Tumyan L, Winkler NS, Wolverton DE, Bergman MA, Kumar R, Stehman K. NCCN Guidelines Insights: Breast Cancer Screening and Diagnosis, Version 1.2023. Journal of National Comprehensive Cancer Network 21(9):900-909, 2023. e-Pub 2023. PMID: 37673117.
Xie CL, Whitman GJ, Middleton LP, Bevers TB, Bedrosian I, Chung HL. Isolated Flat Epithelial Atypia: Upgrade Outcomes After Multidisciplinary Review–Based Management Using Excision or Imaging Surveillance. Journal of Breast Imaging 5(5):575-584, 2023. e-Pub 2023. PMID: 37744722.
Chung HL, Bevers TB, Legha RS, Speer ME, Tso HH, Sun J, Leung JW. Nipple Discharge Imaging Evaluation with Mammography, Ultrasound, Galactography, and MRI. Acad Radiol 30(5):783-797, 2023. e-Pub 2023. PMID: 35760711.
Kilgore LJ, Yi M, Bevers T, Coyne R, Lazzaro M, Lane D, Albarracin C, Bedrosian I. Risk of Breast Cancer in Selected Women with Atypical Ductal Hyperplasia Who do not Undergo Surgical Excision. Ann Surg 276(6):E932-E936, 2022. e-Pub 2021. PMID: 33914469.
Niemiro, GM, Coletta, AM, Agha, N, Mylabathula, PL, Baker, FL, Brewster, A, Bevers, TB, Fuentes-Mattei, E, Basen-Engquist, KM, Katsanis, E, Gilchrist, SC, Simpson, RJ. Salutary effects of moderate but not high intensity aerobic exercise training on the frequency of peripheral T-cells associated with immunosenescence in older women at high risk of breast cancer. Immunity and Ageing 19(1), 2022. e-Pub 2022. PMID: 35321743.
Kilgore LJ, Yi M, Bevers T, Coyne R, Marita L, Albarracin C, Bedrisian I. Risk of Breast Cancer in Selected Women With Atypical Ductal Hyperplasia Who do not Undergo Surgical Excision. Ann Surg:932-936, 2022. e-Pub 2022. PMID: 33914469.
Nemati Shafaee M, Goutsouliak K, Lin H, Bevers TB, Gutierrez-Barrera A, Bondy M, Arun B. Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers. Breast Cancer Res Treat 196(1):143-152, 2022. e-Pub 2022. PMID: 36006499.
Brannon GE, Madison R, Cho P, Baum M, Beg MS, Bevers T, Schembre SM, Basen-Engquist K, Liao Y. A qualitative study to explore the acceptability and usefulness of personalized biofeedback to motivate physical activity in cancer survivors. Digit Health 8, 2022. e-Pub 2022. PMID: 36238756.
Chung HL, Bevers TB, Legha RS, Speer ME, Tso HH, Sun J, Leung JW. Nipple Discharge Imaging Evaluation with Mammography, Ultrasound, Galactography, and MRI. Acad Radiol S1076-6332(22), 2022. e-Pub 2022. PMID: 35760711.
Niemiro GM, Coletta AM, Agha NH, Mylabathula PL, Baker FL, Brewster AM, Bevers TB, Fuentes-Mattei E, Basen-Engquist K, Katsanis E, Gilchrist SC, Simpson RJ. Correction: Salutary effects of moderate but not high intensity aerobic exercise training on the frequency of peripheral T-cells associated with immunosenescence in older women at high risk of breast cancer: a randomized controlled trial. Immun Ageing 19(1):30, 2022. e-Pub 2022. PMID: 35676680.
Housten AJ, Hoover DS, Britton M, Bevers TB, Street RL, McNeill LH, Strong LL, Hersch J, McCaffery K, Volk RJ. Perceptions of Conflicting Breast Cancer Screening Recommendations Among Racially/Ethnically Diverse Women: a Multimethod Study. J Gen Intern Med 37(5):1145-1154, 2022. e-Pub 2022. PMID: 35015260.
Coletta AM, Agha NH, Baker FL, Niemiro GM, Mylabathula PL, Brewster AM, Bevers TB, Fuentes-Mattei E, Basen-Engquist K, Gilchrist SC, Simpson RJ. The impact of high-intensity interval exercise training on NK-cell function and circulating myokines for breast cancer prevention among women at high risk for breast cancer. Breast Cancer Res Treat 187(2):407-416, 2021. e-Pub 2021. PMID: 33555464.
Asaad M, Offodile AC, Santanelli Di Pompeo F, Bevers TB, Stelly S, Carew LA, Barnea Y, Miranda RN, Butler CE, Clemens MW. Management of Symptomatic Patients with Textured Implants. Plast Reconstr Surg 147(5S):58S-68S, 2021. e-Pub 2021. PMID: 33890882.
Bhatia S, Palomares MR, Hageman L, Chen Y, Landier W, Smith K, Umphrey H, Reich CA, Zamora KW, Armenian SH, Bevers TB, Blaes A, Henderson T, Hodgson D, Hudson MM, Korde LA, Melin SA, Merajver SD, Overholser L, Pruthi S, Wong FL, Garber JE. A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at risk for Breast Cancer. Clin Cancer Res 27(4):967-974, 2021. e-Pub 2021. PMID: 33272980.
Bonanni B, Serrano D, Maisonneuve P, Veronesi G, Johansson H, Aristarco V, Varricchio C, Cazzaniga M, Lazzeroni M, Rampinelli C, Bellomi M, Vecchi M, Spaggiari L, Vornik L, Brown PH, Beavers T, Guerrieri-Gonzaga A, Szabo E. Low-Dose Aspirin in High-Risk Individuals With Screen-Detected Subsolid Lung Nodules: A Randomized Phase II Trial. JNCI Cancer Spectr 4(6):pkaa096, 2020. e-Pub 2020. PMID: 33409459.
Bayraktar S, Baghaki S, Wu J, Liu DD, Gutierrez-Barrera AM, Bevers TB, Valero V, Sneige N, Arun BK. Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study. Cancer Prev Res (Phila) 13(9):795-802, 2020. e-Pub 2020. PMID: 32513785.
Yalniz C, Campbell D, Le-Petross C, Shin K, Bevers TB, Hess KR, Whitman GJ. The role of magnetic resonance imaging in patients with palpable breast abnormalities and negative mammographic and sonographic findings. Breast J 26(7):1289-1295, 2020. e-Pub 2020. PMID: 32108973.
Liao Y, Basen-Engquist KM, Urbauer DL, Bevers TB, Hawk E, Schembre SM. Using Continuous Glucose Monitoring to Motivate Physical Activity in Overweight and Obese Adults: A Pilot Study. Cancer Epidemiol Biomarkers Prev 29(4):761-768, 2020. e-Pub 2020. PMID: 32066620.
Volk RJ, Mendoza TR, Hoover DS, Nishi SPE, Choi NJ, Bevers TB. Reliability of self-reported smoking history and its implications for lung cancer screening. Prev Med Rep 17:101037, 2020. e-Pub 2020. PMID: 31934536.
Housten AJ, Kamath GR, Bevers TB, Cantor SB, Dixon N, Hite A, Kallen MA, Leal VB, Li L, Volk RJ. Does Animation Improve Comprehension of Risk Information in Patients with Low Health Literacy? A Randomized Trial. Med Decis Making 40(1):272989X19890296, 2020. e-Pub 2020. PMID: 31795820.
Volk RJ, Lowenstein LM, Leal VB, Escoto KH, Cantor SB, Munden RF, Rabius VA, Bailey L, Cinciripini PM, Lin H, Housten AJ, Luckett PG, Esparza A, Godoy MC, Bevers TB. Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: A Randomized Clinical Trial. JAMA Netw Open 3(1):e1920362, 2020. e-Pub 2020. PMID: 32003822.
Coletta AM, Brewster AM, Chen M, Li Y, Bevers TB, Basen-Engquist K, Gilchrist SC. High-Intensity Interval Training Is Feasible in Women at High Risk for Breast Cancer. Med Sci Sports Exerc 51(11):2193-2200, 2019. e-Pub 2019. PMID: 31269007.
Crew KD, Anderson GL, Hershman DL, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, Kairouz SS, Kuwajerwala N, Bevers T, Doster JE, Zarwan C, Kruper L, Minasian LM, Ford L, Arun B, Neuhouser M, Goodman GE, Brown PH. Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). Cancer Prev Res (Phila) 12(7):481-490, 2019. e-Pub 2019. PMID: 31138522.
Hoover DS, Pappadis MR, Housten AJ, Krishnan S, Weller SC, Giordano SH, Bevers TB, Goodwin JS, Volk RJ. Preferences for Communicating about Breast Cancer Screening Among Racially/Ethnically Diverse Older Women. Health Commun 34(7):1-5, 2019. e-Pub 2019. PMID: 29373069.
Phalak KA, Milton DR, Yang WT, Bevers TB, Dogan BE. Supplemental ultrasound screening in patients with a history of lobular neoplasia. Breast J 25(2):250-256, 2019. e-Pub 2019. PMID: 30675929.
Coletta AM, Marquez G, Thomas P, Thoman W, Bevers T, Brewster AM, Hawk E, Basen-Engquist K, Gilchrist SC. Clinical factors associated with adherence to aerobic and resistance physical activity guidelines among cancer prevention patients and survivors. PLoS One 14(8):e0220814, 2019. e-Pub 2019. PMID: 31369653.
Holmberg, C, Bandos, H, McCaskill-Stevens, W, Wickerham, DL, Battaglia, T, Bevers, TB, Fagerlin, A. Results from NRG oncology/NSABP protocol DMP-1. Annals of oncology : official journal of the European Society for Medical Oncology 29:viii88, 2018. e-Pub 2018. PMID: 32138108.
Lowenstein LM, Escoto KH, Leal VB, Bailey L, Bevers TB, Cantor SB, Cinciripini PM, Jacobs LE, Esparza A, Godoy MC, Housten AJ, Lin H, Luckett P, Munden RF, Rabius V, Volk RJ. Randomized trial of a patient-centered decision aid for promoting informed decisions about lung cancer screening: Implementation of a PCORI study protocol and lessons learned. Contemp Clin Trials 72:26-34, 2018. e-Pub 2018. PMID: 30010085.
Housten AJ, Pappadis MR, Krishnan S, Weller SC, Giordano SH, Bevers TB, Volk RJ, Hoover DS. Resistance to discontinuing breast cancer screening in older women: A qualitative study. Psychooncology 27(6):1635-1641, 2018. e-Pub 2018. PMID: 29575590.
Brewster AM, Thomas P, Brown P, Coyne R, Yan Y, Checka C, Middleton L, Do KA, Bevers T. A System-Level Approach to Improve the Uptake of Antiestrogen Preventive Therapy among Women with Atypical Hyperplasia and Lobular Cancer In Situ. Cancer Prev Res (Phila) 11(5):295-302, 2018. e-Pub 2018. PMID: 29618460.
Bojadzieva J, Amini B, Day SF, Jackson TL, Thomas PS, Willis BJ, Throckmorton WR, Daw NC, Bevers TB, Strong LC. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic. Fam Cancer 17(2):287-294, 2018. e-Pub 2017. PMID: 28988289.
Blakeslee SB, McCaskill-Stevens W, Parker PA, Gunn CM, Bandos H, Bevers TB, Battaglia TA, Fagerlin A, Müller-Nordhorn J, Holmberg C. Deciding on breast cancer risk reduction: The role of counseling in individual decision-making - A qualitative study. Patient Educ Couns 100(12):2346-2354, 2017. e-Pub 2017. PMID: 28734560.
Holmberg C, Bandos H, Fagerlin A, Bevers TB, Battaglia TA, Wickerham DL, McCaskill-Stevens WJ. NRG Oncology/National Surgical Adjuvant Breast and Bowel Project Decision-Making Project-1 Results: Decision Making in Breast Cancer Risk Reduction. Cancer Prev Res (Phila) 10(11):625-634, 2017. e-Pub 2017. PMID: 28978566.
Guo M, Khanna A, Wang J, Dawlett MA, Kologinczak TL, Lyons GR, Bassett RL, Sneige N, Gong Y, Bevers TB. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening. Cancer 125(8):644-651, 2017. e-Pub 2017. PMID: 28498639.
Raghavendra A, Sinha AK, Le-Petross HT, Garg N, Hsu L, Patangan M, Bevers TB, Shen Y, Banu A, Tripathy D, Bedrosian I, Barcenas CH. Mammographic breast density is associated with the development of contralateral breast cancer. Cancer 123(11):1935-1940, 2017. e-Pub 2017. PMID: 28135395.
Hovick SR, Bevers TB, Vidrine JI, Kim S, Dailey PM, Jones LA, Peterson SK. User Perceptions and Reactions to an Online Cancer Risk Assessment Tool: a Process Evaluation of Cancer Risk Check. J Cancer Educ 32(1):141-147, 2017. e-Pub 2017. PMID: 26546305.
Menen RS, Ganesan N, Bevers T, Ying J, Coyne R, Lane D, Albarracin C, Bedrosian I. Long-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal Hyperplasia. Ann Surg Oncol 24(1):70-76, 2017. e-Pub 2017. PMID: 27573525.
Lowenstein LM, Richards VF, Leal VB, Housten AJ, Bevers TB, Cantor SB, Cinciripini PM, Cofta-Woerpel LM, Escoto KH, Godoy MC, Linder SK, Munden RF, Volk RJ. A brief measure of smokers' knowledge of lung cancer screening with low-dose computed tomography. Prev Med Rep 4:351-6, 2016. e-Pub 2016. PMID: 27512650.
Bradford A, Fellman B, Urbauer D, Bevers T. Effect of routine screening for sexual problems in a breast cancer survivorship clinic. Psychooncology 25(11):1375-1378, 2016. e-Pub 2016. PMID: 26449709.
Atkinson RL, El-Zein R, Valero V, Lucci A, Bevers TB, Fouad T, Liao W, Ueno NT, Woodward WA, Brewster AM. Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control 27(3):359-66, 2016. e-Pub 2016. PMID: 26797453.
Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C, McArthur HL, Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. J Hum Nutr Diet 28(3):272-82, 2015. e-Pub 2015. PMID: 24646362.
Day, S, Bevers, TB. Quality of life in MAP.3 (mammary prevention 3). Breast Diseases 26(2):123-124, 2015. e-Pub 2015.
Day, S, Bevers, TB. Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Breast Diseases 26(2):128-130, 2015. e-Pub 2015.
Allweis TM, Strauss L, Malyutin Z, Kapov-Kagan AB, Novikov I, Bevers TB, Iacobelli S, Sandri MT, Bitterman A, Engelman P, Piura B, Rosenberg M, Yahalom G. An autoantibody based protein microarray blood test to enhance the specificity of a negative screening mammogram. Scientific Research 4(1):22-38, 2015. e-Pub 2015.
Middleton LP, Sneige N, Coyne R, Yu S, Dong W, Dempsey P, Bevers TB. Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow-up in a multidisciplinary setting. Cancer Medicine 3(3):492-9, 2014. e-Pub 2014. PMID: 24639339.
Volk RJ, Linder SK, Leal VB, Rabius V, Cinciripini PM, Kamath GR, Munden RF, Bevers TB. Feasibility of a patient decision aid about lung cancer screening with low-dose computed tomography. Preventive Medicine 62(62):60-63, 2014. e-Pub 2014. PMID: 24518006.
Day, S, Bevers, TB. Guidelines challenge current practice and perceptions of breast cancer risk reduction therapy. Breast Diseases 25(3):203-205, 2014. e-Pub 2014.
Versace F, Engelmann JM, Jackson EF, Slapin A, Cortese KM, Bevers TB, Schover LR. Brain responses to erotic and other emotional stimuli in breast cancer survivors with and without distress about low sexual desire: a preliminary fMRI study. Brain Imaging Behav 7(4):533-42, 2013. e-Pub 2013. PMID: 23955492.
Nayak A, Carkaci S, Gilcrease MZ, Liu P, Middleton LP, Bassett RL, Zhang J, Zhang H, Coyne RL, Bevers TB, Sneige N, Huo L. Benign papillomas without atypia diagnosed on core needle biopsy: experience from a single institution and proposed criteria for excision. Clin Breast Cancer 13(6):1-11, 2013. e-Pub 2013. PMID: 24119786.
Yahalom G, Weiss D, Novikov I, Bevers TB, Radvanyi LG, Liu M, Piura B, Iacobelli S, Sandri MT, Cassano E, Allweis TM, Bitterman A, Engelman P, Vence LM, Rosenberg MM. An antibody-based blood test utilizing a panel of biomarkers as a new method for improved breast cancer diagnosis. Biomark Cancer 5:71-80, 2013. e-Pub 2013. PMID: 24324350.
Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 119(19):3454-61, 2013. e-Pub 2013. PMID: 23983047.
Reddy N, Ninan T, Tabar L, Bevers T. The results of a breast cancer screening camp at a district level in rural India. Asian Pacific J Cancer Prev 13(12):6067-72. e-Pub 2013. PMID: 23464405.
Guo M, Gong Y, Wang J, Dawlett M, Patel S, Liu P, Bevers TB, Sneige N. The role of human papillomavirus type 16/18 genotyping in predicting high-grade cervical/vaginal intraepithelial neoplasm in women with mildly abnormal Papanicolaou results. Cancer Cytopathol 121(2):79-85, 2013. e-Pub 2013. PMID: 23225501.
Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila) 5(9):1144-54, 2012. e-Pub 2012. PMID: 22827973.
Reddy, N, Ninan, T, Tabár, L, Bevers, TB. The results of a breast cancer screening camp at a district level in rural india. Asian Pacific Journal of Cancer Prevention 13(12):6067-6072, 2012. e-Pub 2012. PMID: 23464405.
Guo M, Wang J, Dawlett M, Patel S, Liu P, Gong Y, Bevers T, Sneige N. Risk profiling using HPV genotyping in women with mildly abnormal Pap results. Cytojournal 8(16A), 2011. e-Pub 2011.
Mazouni C, Sneige N, Rouzier R, Balleyguier C, Bevers T, André F, Vielh P, Delaloge S. A nomogram to predict for malignant diagnosis of BI-RADS Category 4 breast lesions. J Surg Oncol 102(3):220-4, 2010. e-Pub 2010. PMID: 20740578.
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N. Update of the NSABP Study of Tamoxifen and Raloxifene (STAR). Cancer Prev Res (Phila Pa) 3(6):696-706, 2010. e-Pub 2010. PMID: 20404000.
Espeland MA, Shumaker SA, Limacher M, Rapp SR, Bevers TB, Barad DH, Coker LH, Gaussoin SA, Stefanick ML, Lane DS, Maki PM, Study Groups RSFTWAC. Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. Journal of Women's Health 19(3):371-9, 2010. e-Pub 2010. PMID: 20136553.
Legault C, Maki PM, Resnick SM, Coker L, Hogan P, Bevers TB, Shumaker SA. Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. J Clin Oncol 27(31):5144-52, 2009. e-Pub 2009. PMID: 19770382.
Cyrus-David M, King J, Bevers T, Robinson E. Validity assessment of the Breast Cancer Risk Reduction Health Belief scale. Cancer 115(21):4907-16, 2009. e-Pub 2009. PMID: 19637346.
Lu J, Wei Q, Bondy ML, Brewster AM, Bevers TB, Yu TK, Buchholz TA, Meric-Bernstam F, Hunt KK, Singletary SE, Wang LE. Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged
Bevers, TB. Raloxifene. Expert Review of Obstetrics and Gynecology 3(3):277-285, 2008. e-Pub 2008.
Dong W, Berry DA, Bevers TB, Kau SW, Hsu L, Theriault RL, Shen Y. Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: The University of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev 17(5):1096-103, 2008. e-Pub 2008. PMID: 18483331.
Guo M, Patel SJ, Chovanec M, Jan YJ, Tarco E, Bevers TB, Anderson K, Sneige N. A human papillomavirus testing system in women with abnormal Pap results: a comparison study with follow-up biopsies. Acta Cytol 51(5):749-54, 2007. e-Pub 2007. PMID: 17910345.
Bevers, TB. 2-5 The Influence of Family History on Breast Cancer Risk in Women With Biopsy-Confirmed Benign Breast Disease. Breast Diseases 18(2):140-141, 2007. e-Pub 2007.
Bevers, TB. 1-6 Breast Cancer Risk Estimates for Relatives of White and African American Women With Breast Cancer in the Women's Contraceptive and Reproductive Experiences Study. Breast Diseases 18(1):32, 2007. e-Pub 2007.
Bevers, TB. Cyclical Mastalgia and Breast Cancer Risk. Breast Diseases 18(1):30-31, 2007. e-Pub 2007.
Bevers, TB. Raloxifene. Breast Diseases 18(1):24-25, 2007. e-Pub 2007.
Bevers, TB. 1-2 Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women. Breast Diseases 18(1):26-27, 2007. e-Pub 2007.
Bevers, TB. Breast Cancer Risk Assessment and Prevention. Breast Diseases 17(4):339, 2007. e-Pub 2007.
Bevers, TB. 2-4 The Gail Model Predicts Breast Cancer in Women With Suspicious Radiographic Lesions. Breast Diseases 17(2):136, 2006. e-Pub 2006.
Shen Y, Dong W, Esteva FJ, Kau SW, Theriault RL, Bevers TB. Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?. Breast Cancer Res Treat 102(3):347-56, 2006. e-Pub 2006. PMID: 17028980.
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, Wolmark N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727-41, 2006. e-Pub 2006. PMID: 16754727.
Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97(22):1652-62, 2005. e-Pub 2005. PMID: 16288118.
Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 103(6):1122-8, 2005. e-Pub 2005. PMID: 15712375.
Bevers, TB. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. Breast Diseases 16(2):142-143, 2005. e-Pub 2005.
Bevers, TB. What factors are associated with diagnostic follow-up after abnormal mammograms? Findings from a US national survey. Breast Diseases 16(1):25, 2005. e-Pub 2005.
Bevers, TB. A prospective study of diet and benign breast disease. Breast Diseases 16(1):34-35, 2005. e-Pub 2005.
Bevers, TB. Association between uterine serous carcinoma and breast cancer. Breast Diseases 16(1):28, 2005. e-Pub 2005.
Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, Eifel P, Bevers TB, Levenback CF, Gershenson DM, Bodurka DC. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 23(30):7428 -36, 2005. e-Pub 2005. PMID: 16234510.
Singletary SE, Atkinson EN, Hoque A, Sneige N, Sahin AA, Fritsche HA, Jr, Lotan R, Lu T, Hittelman WN, Bevers TB, Stelling CB, Lippman SM. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 8(9):2835-42, 2002. e-Pub 2002. PMID: 12231524.
Bevers, TB. Breast cancer chemoprevention. Biomedicine and Pharmacotherapy 55(9-10):559-564, 2001. e-Pub 2001. PMID: 11769967.
Singletary, SE, Lieberman R, Atkinson N, Sneige N, Sahin A, Tolley S, Colchin M, Bevers T, Stelling C, Fornage B, Fritsche H, Hittelman W, Kelloff G, Lippman SM. Novel translational model for breast cancer chemoprevention study: Accrual to a presurgical intervention with tamoxifen and N-[4-Hydroxyphenyl] retinamide. Cancer Epidemiology, Biomarkers and Prevention 9:1087-1090, 2000. e-Pub 2000.
Singletary, ES, Lieberman, R, Atkinson, N, Sneige, N, Sahin, AA, Tolley, S, Colchin, M, Bevers, TB, Stelling, C, Fornage, BD, Fritsche, HA, Hittelman, WN, Kelloff, GJ, Lippman, SM. Novel translational model for breast cancer chemoprevention study. Cancer Epidemiology Biomarkers and Prevention 9(10):1087-1090, 2000. e-Pub 2000. PMID: 11045792.

Invited Articles

Bevers TB, Helvie M, Bonaccio E, Calhoun KE, Daly MB, Farrar WB, Garber JE, Gray R, Greenberg CC, Greenup R, Hansen NM, Harris RE, Heerdt AS, Helsten T, Hodgkiss L, Hoyt TL, Huff JG, Jacobs L, Lehman CD, Monsees B, Niell BL, Parker CC, Pearlman M, Philpotts L, Shepardson LB, Smith ML, Stein M, Tumyan L, Williams C, Bergman MA, Kumar R. Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16(11):1362-1389, 2018. e-Pub 2018. PMID: 30442736.
Krishnamurthy S, Bevers T, Kuerer HM, Smith B, Yang WT. Paradigm Shifts in Breast Care Delivery: Impact of Imaging in a Multidisciplinary Environment. AJR Am J Roentgenol 208(2):248-255, 2017. e-Pub 2017. PMID: 27929664.
Austin A, Damani S, Bevers T. Clinical Approach for Patient-Centered Physical Activity Assessment and Interventions. Clin J Oncol Nurs 20(6):S2, 2016. e-Pub 2016. PMID: 27857272.
Bevers T, Bibbins-Domingo K, Oeffinger KC, Smith ML. Controversies in Breast Cancer Screening Strategies. J Natl Compr Canc Netw 14(5 Suppl):651-3, 2016. e-Pub 2016. PMID: 27226505.
Pruthi S, Heisey RE, Bevers TB. Chemoprevention for Breast Cancer. Ann Surg Oncol 22(10):3230-5, 2015. e-Pub 2015. PMID: 26202562.
Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R. National Comprehensive Cancer Network clinical practice guidelines in oncology: breast cancer risk reduction. J Natl Compr Canc Netw 13(7):880-915, 2015. e-Pub 2015. PMID: 26150582.
Bevers TB, Bedrosian I, Middleton L P, Scoggins ME. Current Multidisciplinary Management of High-Risk Breast Lesions. Curr Breast Cancer Rep(7):81-89, 2015. e-Pub 2015.
Pruthi S, Heisey R, Bevers T. Personalized assessment and management of women at risk for breast cancer in North America. Womens Health (Lond Engl) 11(2):213-224, 2015. e-Pub 2015. PMID: 25776295.
Litton JK, Bevers TB, Arun BK. Exemestane in the prevention setting. Ther Adv Med Oncol 4(3):107-12, 2012. e-Pub 2012. PMID: 22590484.
Krishnamurthy S, Bevers T, Kuerer H, Yang WT. Multidisciplinary considerations in the management of high-risk breast lesions. AJR Am J Roentgenol 198(2):W132-40, 2012. e-Pub 2012. PMID: 22268202.
Bevers TB. Breast Cancer Prevention: An Update of the STAR Trial. Curr Treat Options Oncol 11(3):66-9, 2010. e-Pub 2010. PMID: 21061192.
Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH. National Comprehensive Cancer Network clinical practice guidelines in oncology: breast cancer risk reduction. J Natl Compr Canc Netw 8(10):1112-46, 2010. e-Pub 2010. PMID: 20971838.
Bevers TB, Anderson BO, Bonaccio E, Buys S, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TN, Williams C, Yankeelov T, Yaneeklov T, Cancer Network NC. National Comprehensive Cancer Network clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 7(10):1060-96, 2009. e-Pub 2009. PMID: 19930975.
Bevers TB. Alcohol and Cancer Incidence in Women. Curr Oncol Rep 11(6):417-419, 2009. e-Pub 2009. PMID: 19840518.
Bevers TB. Ultrasound for the screening of breast cancer. Curr Oncol Rep 10(6):527-8, 2008. e-Pub 2008. PMID: 18928668.
Mahoney MC, Bevers T, Linos E, Willett WC. Opportunities and strategies for breast cancer prevention through risk reduction. CA Cancer J Clin 58(6):347-371, 2008. e-Pub 2008. PMID: 18981297.
Bevers TB. Raloxifene: An agent for breast cancer prevention. Expert Rev Obstet Gynecol 3(3):277-85, 2008. e-Pub 2008.
Bevers TB. CT screening for lung cancer. Curr Oncol Rep 9(6):501-2, 2007. e-Pub 2007. PMID: 17991359.
Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Lawton T, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Seewaldt V, Sellin RV, Shapiro CL, Singletary E, Ward JH, Ward JH. National Comprehensive Cancer Network clinical practice guidelines in oncology: breast cancer risk reduction. J Natl Compr Canc Netw 5(8):676-701, 2007. e-Pub 2007. PMID: 17927926.
Bevers TB. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. J Natl Compr Canc Netw 5(8):719-24, 2007. e-Pub 2007. PMID: 17927929.
Bevers TB. Raloxifene and the prevention of breast cancer. Expert Opin Pharmacother 7(16):2301-07, 2006. e-Pub 2006. PMID: 17059385.
Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T, Jonasch E, Aldape K, Liu J, James RD, Ferguson CG, Xu Y, Prestwich GD, Mills GB. Lysophosphatidic acid production and action: Validated targets in cancer?. J Cell Biochem 92(6):1115-40, 2004. e-Pub 2004. PMID: 15258897.
Bevers TB, Anderson BO, Bonaccio E, Borgen PI, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Helvie M, Hoover S, Krontiras H, Shaw S, Singletary E, Sugg Skinner C, Smith ML, Tsangaris TN, Wiley EL, Williams C, Williams C. National Comprehensive Cancer Network clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 1(5):242-263, 2003. e-Pub 2003. PMID: 16687096.
Bevers TB. Breast cancer chemoprevention: current clinical practice and future direction. Biomed Pharmacother 55:559-564, 2001. e-Pub 2001.
Carlson, R, Barakat R, Bevers T, Daly MB, Edge S, Garber JE, Gradishar W, Mahoney M, Sellin RV, Shapiro C, Singletary E, Theriault R, Ward J, Whittemore A, Williams C, Winer E. NCCN Practice Guideline: Breast Cancer Risk-Reduction. Oncology 13:241-254, 1999. e-Pub 1999.
Bevers T. Evidence-based Cancer Screening. Highlights Oncol Pract 16:91-99, 1999. e-Pub 1999.
Bevers T. How to Perform an Adequate Clinical Breast Examination: A Photographic Guide. Primary Care and Cancer, 1999. e-Pub 1999.
Singletary, SE, Bevers T, Dempsey P, Farrar B, Garber J, Harris R, Helvie M, Jacobs M, Pass H, Patterson Smith ML, Tarantolo S, Venta LA. NCCN Practice Guideline: Screening for and Evaluation of Suspicious Breast Lesions. Oncology 12:89-138, 1998. e-Pub 1998.

Review Articles

Housten, AJ, Lowenstein, LM, Hoffman, AS, Jacobs, LE, Zirari, Z, Hoover, DS, Stacey, D, Pratt, GF, Bevers, TB, Volk, R. A Review of the Presentation of Overdiagnosis in Cancer Screening Patient Decision Aids. MDM Policy and Practice 4(2), 2019. e-Pub 2019. PMID: 35187246.
Helvie MA, Bevers TB. Screening Mammography for Average-Risk Women: The Controversy and NCCN's Position. J Natl Compr Canc Netw 16(11):1398-1404, 2018. e-Pub 2018. PMID: 30442738.
Bevers, TB, Bedrosian, I, Middleton, LP, Scoggins, ME. Current Multidisciplinary Management of High-Risk Breast Lesions. Current Breast Cancer Reports 7(2):81-89, 2015. e-Pub 2015.

Professional Educational Materials

Baldwin, D, Bevers T, Drugary M, Gullatte MM, Dow KH, Kaur J, O’Donnell J, Palos G, Phillips J. Competencies for Health Professionals: A multicultural perspective in the promotion of breast, cervical, colorectal and skin health. American Nurses Association, Washington, D.C, 1996.

Editorials

Bevers TB. Breast cancer risk reduction therapy: the low-hanging fruit. J Natl Compr Canc Netw 13(4):376-8, 2015. PMID: 25870373.
Day S, Bevers T. Guidelines Challenge Current Practice and Perceptions of Breast Cancer Risk - Reduction Therapy. Breast Diseases A Year Book Quarterly 25(3):203 - 205, 2014.
Volk RJ, Hawk E, Bevers TB. Should CMS cover lung cancer screening for the fully informed patient?. JAMA 312(12):1193-4, 2014. PMID: 25247511.
Bevers TB. Flaws in CNBSS are Vast, Impact on Screening Recommendations is Nil. The ASCO Post.
Bevers TB. Breast awareness: A shift in the paradigm of breast self-examination. J Natl Compr Canc Netw 7(10):1042-3, 2009. PMID: 19930973.
Harms, S, Early, A, Bevers, TB, Giuliano, AE, Golshan, M, Hertz, IH, Kiel, K, Kivitz, PB, Leitch, AM, Overmoyer, BA, Vargas, HI, Silva, E, Siziopikou, KP, Shriver, CD, Olopade, OI. American Society of Breast Disease Policy Statement on The Use of Breast Magnetic Resonance Imaging. Seminars in Breast Disease 11(2):111-112, 2008.
Bevers TB. Raloxifene: A new paradigm for breast cancer prevention. Breast Diseases: A YearBook Quarterly 18:24-5, 2007.
Bevers TB. Breast self-examination an optional screening modality in national comprehensive cancer network breast cancer screening guidelines. Breast Diseases: A YearBook Quarterly 9:230-31, 1998.
Bevers TB, Lippman, SM. Randomized trial of breast self-examination in Shanghai: Methodology and preliminary results. Breast Disease: A YearBook Quarterly 8:308-309, 1998.

Abstracts

Brannon, G, Ray, M, Cho, P, Baum, M, Beg, M S, Bevers, T, Basen-Engquist, K M, Liao &, Y. Utilizing biofeedback as a behavioral change strategy in overweight and obese cancer survivors to promote physical activity: A focus group analysis. International Society of Behavioral Nutrition and Physical Activity Annual Meeting ISBNPA Xchange 2021:260, 2021. e-Pub 2021.
Y Liao Y, K Basen-Engquist K, D Urbauer D, T Bevers T, E Hawk E, S Schembre S. Using Continuous Glucose Monitoring to Motivate Physical Activity in Overweight and Obese Adults: A Pilot Study. AACR Publications 29(4):761-768, 2020. e-Pub 2020.
Bhatia S, Palomares M, Hageman L, Yanjun C, Landier W, Smith K, Umphrey H, Reich C, Zamora K, Armenian S, Bevers T, Blaes A, Henderson T, Hodgson D, Hudson M, Korde L, Melin S, Merajver S, Overholser L, Pruthi S, Wong L, Garber J. Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Strategy Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adulthood-a Randomized,Placebo-Controlled Double Blinded Phase </b> Trial. BLOOD 134(Issue Supplement_1):3-7, 2019. e-Pub 2019.
Bhatia S, Palomares M, Hageman L, Yanjun C, Landier W, Smith K, Umphrey H, Reich C, Zamora K, Armenian S, Bevers T, Blaes A, Henderson T, Hodgson D, Hudson M, Korde L, Melin S, Merajver S, Overholser L, Pruthi S, Wong L, Garber J. Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Strategy Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adulthood-a Randomized,Placebo-Controlled Double Blinded Phase Trial. BLOOD 134(Issue Supplement_1):3-7, 2019. e-Pub 2019.
Bevers T, Brewster AM, Thomas P, Brown P, Coyne R, Yan Y, Checka C, Middleton L, Do KA. A System-Level Approach to Improve the Uptake of Antiestrogen Preventive Therapy among Women with Atypical Hyperplasia and Lobular Cancer In Situ. Cancer Prev Res (Phila) 11(5):295-302, 2018. e-Pub 2018. PMID: 29618460.
Coletta AM, Marquez G, Thomas P, Thoman W, Austin A, Bevers T, Brewster A, Hawk E, Basen-Engquist K, Lakoski SG. Adherence to Physical Activity Guidelines in a Cancer Prevention and Control Setting: The Impact of Body Mass Index, 2016. e-Pub 2016.
Austin A, Thoman W, Scroggs S, Damani S, Bevers TB. Physical Activity Algorithm In A Comprehensive Cancer Center.: 1879 Board #31 June 2, 3: 30 PM - 5: 00 PM. Med Sci Sports Exerc 48(5 Suppl 1):516, 2016. e-Pub 2016. PMID: 27360704.
Austin A, Thoman W, Scroggs S, Damani S, Bevers TB. Physical Activity Algorithm In A Comprehensive Cancer Center.: 1879 Board #31 June 2, 3: 30 PM - 5: 00 PM. Med Sci Sports Exerc 48(5 Suppl 1):516, 2016. e-Pub 2016. PMID: 27360704.
Blakeslee SB, Parker PA, Gunn C, Bandos H, Battaglia TA, Bevers TB, McCaskill-Stevens W, Muller-Nordhorn J, Holmberg C. Abstracts of the Cancer and Primary Care Research International (Ca - PRI). Network 8th Annual Meeting, 2015. e-Pub 2015.
Khanna A, Dawlett M, Kologinczak T, Wang J, Patel S, Bevers T, Sneige N, Guo M. Can HPV testing be used as a first-line screening test for cervical cancer prevention? Three-year cumulative risk of CIN2+ in women aged 30 years and older screened by Pap and HPV co-testing. Journal of the American Society of Cytopathology 3(5):S38, 2014. e-Pub 2014.
Gilmore KR, Damani S, King RM, Nelson B, Austin A, Scroggs S, Bevers TB, Zandstra FA. A program evaluation of best practice methods to assess integrated health needs for breast cancer survivors. J Clin Oncol 32 (suppl 30; abstr 111), 2014. e-Pub 2014.
Khanna A, Dawlett M, Kologinczak T, Wang J, Patel S, Bevers T, Sneige N, Guo M. Can HPV testing be used as a first-line screening test for cervical cancer prevention? Three-year cumulative risk of CIN2+ in women aged 30 years and older screened by Pap and HPV co-testing. Journal of the American Society of Cytopathology 3(5):S38, 2014. e-Pub 2014.
Volk RJ, Linder SK, Leal VB, Rabius V, Cinciripini PM, Kamath GR, Munden RF, Bevers TB. Patients' reactions to a decision aid about lung cancer screening with low-dose spiral computed tomography: an uncontrolled trial. J Clin Oncol 31(suppl; abstr 1564), 2013. e-Pub 2013.
Volk RJ, Linder SK, Leal VB, Rabius V, Cinciripini PM, Kamath GR, Munden RF, Bevers TB. Patients' reactions to a decision aid about lung cancer screening with low-dose spiral computed tomography: an uncontrolled trial. J Clin Oncol 31(suppl; abstr 1564), 2013. e-Pub 2013.
Ping J, Kologinczak T, Dawlett M, Bevers T, Sneige N, Guo M. Risk of CIN2+ in Women 30 Years and Older with Negative Pap and Positive Hybrid Capture 2 HPV DNA Testing Results. Journal of the American Society of Cytopathology 1(1), 2012. e-Pub 2012.
Wang J, Kologinczak T, Dawlett M, Bevers T, Sneige N, Guo M. Risk of CIN2+ in women 30 Years and older with negative pap and positive hybrid capture 2 HPV DNA testing results. Journal of the American Society of Cytopathology 1(1):S52, 2012. e-Pub 2012.
Dawlett M, Kologinczak T, Wang J, Sneige N, Bevers T, Guo M. Three-year follow-up for women 30 years and older with negative pap and negative hybrid capture 2 HPV DNA testing results. Journal of the American Society of Cytopathology 1(1):S40, 2012. e-Pub 2012.
Dawlett M, Kologinczak T, Wang J, Sneige N, Bevers T, Guo M. Three-year follow-up for women 30 years and older with negative pap and negative hybrid capture 2 HPV DNA testing results. Journal of the American Society of Cytopathology 1(1):S40, 2012. e-Pub 2012.
Wang J, Kologinczak T, Dawlett M, Bevers T, Sneige N, Guo M. Risk of CIN2+ in women 30 Years and older with negative pap and positive hybrid capture 2 HPV DNA testing results. Journal of the American Society of Cytopathology 1(1):S52, 2012. e-Pub 2012.
Crew KD, Lippman S, Hershman DL, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArhtur H, Vornik L, Cornelison T. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of Polyphenon E in women with a history of hormone receptor-negative breast cancer. Cancer Prevention Research 4(10 Supplement):CN06-02, 2011. e-Pub 2011.
Crew KD, Lippman S, Hershman DL, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArhtur H, Vornik L, Cornelison T. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of Polyphenon E in women with a history of hormone receptor-negative breast cancer. Cancer Prevention Research 4(10 Supplement):CN06-02, 2011. e-Pub 2011.
Morrow PKH, Bevers TB, Zandstra F, Russell L. Multidisciplinary care of the breast cancer survivor: an innovative approach. Breast Cancer Symposium. J Clin Oncol 29(suppl 27; abstr 206), 2011. e-Pub 2011.
Morrow PKH, Bevers TB, Zandstra F, Russell L. Multidisciplinary care of the breast cancer survivor: an innovative approach. Breast Cancer Symposium. J Clin Oncol 29(suppl 27; abstr 206), 2011. e-Pub 2011.
Crew KD, Brown P, Greenlee H, Bevers T, Arun B, Hudis C, McArthur HL, Vornik L, Cornelison TL, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose-escalation study of polyphenon E in women with a history of hormone receptor-negative breast cancer. J Clin Oncol (ASCO Meeting Abstracts) 28:No. 15_suppl(May 20 Supplement), 2010. e-Pub 2010.
Lu KH, Skates S, Bevers TB, Newland W, Moore RG, Leeds L, Harris S, Adeyinka OW, Fritshe HA, Bast RC. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). J Clin Oncol (ASCO Meeting Abstracts) 28:No. 15_suppl(May 20 Supplement), 2010. e-Pub 2010.
Lu KH, Skates S, Bevers TB, Newland W, Moore RG, Leeds L, Harris S, Adeyinka OW, Fritshe HA, Bast RC. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). J Clin Oncol (ASCO Meeting Abstracts) 28:No. 15_suppl(May 20 Supplement), 2010. e-Pub 2010.
Crew KD, Brown P, Greenlee H, Bevers T, Arun B, Hudis C, McArthur HL, Vornik L, Cornelison TL, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose-escalation study of polyphenon E in women with a history of hormone receptor-negative breast cancer. J Clin Oncol (ASCO Meeting Abstracts) 28:No. 15_suppl(May 20 Supplement), 2010. e-Pub 2010.
Olson AL, Bevers T, Guzman M, Theriault RL, Hortobagyi GN, Hahn KM. Cervical and colorectal cancer screening among breast cancer (BrCa) survivors followed in either a breast center (BC) or a breast survivorship clinic (SvC) at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol (ASCO Meeting Abstracts) 27:No. 15S(May 20 Supplement), 2009. e-Pub 2009.
Olson AL, Bevers T, Guzman M, Theriault RL, Hortobagyi GN, Hahn KM. Cervical and colorectal cancer screening among breast cancer (BrCa) survivors followed in either a breast center (BC) or a breast survivorship clinic (SvC) at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol (ASCO Meeting Abstracts) 27:No. 15S(May 20 Supplement), 2009. e-Pub 2009.
Johnson CM, Ensor J, Broglio K, Smolenski D, Ravdin P, Amos C, Meric-Bernstam F, Brewster A, Bevers T, Arun B, Berry D. Building a predictive breast cancer risk model. AMIA Annu Symp Proc:995, 2007. e-Pub 2007. PMID: 18694095.
Dong W, Berry D, Bevers T, Shu-Wan K, Hsu L, Theriault R, Shen Y. Prognostic role of detection method in breast cancer: M.D. Anderson Cancer Center experience. Proceedings of the American Association for Cancer Research Meeting, Los Angeles, 2007. e-Pub 2007.
Dong W, Berry D, Bevers T, Shu-Wan K, Hsu L, Theriault R, Shen Y. Prognostic role of detection method in breast cancer: M.D. Anderson Cancer Center experience. Proceedings of the American Association for Cancer Research Meeting, Los Angeles, 2007. e-Pub 2007.
Wickerham DL, Constantino JP, Vogel V, Cronin W, Cecchini R, Atkins J, et al BT. The study of tamoxifen and raloxifene (STAR): initial findings from the NSABP P-2 breast cancer prevention study. J Clin Oncol (ASCO Meeting Abstracts) 24:No. 18S(June 20 Supplement), 2006. e-Pub 2006.
Wickerham DL, Constantino JP, Vogel V, Cronin W, Cecchini R, Atkins J, et al BT. The study of tamoxifen and raloxifene (STAR): initial findings from the NSABP P-2 breast cancer prevention study. J Clin Oncol (ASCO Meeting Abstracts) 24:No. 18S(June 20 Supplement), 2006. e-Pub 2006.
Cristofanilli, M, Yamamura Y, Kau SW, Bevers TB, Strom SS, Patangan MG, Hsu LM, Krishnamurthy S, Hortobagyi GN. Thyroid hormones and breast cancer: primary hypothyroidism is associated with a reduced incidence of primary breast cancer. Proceedings of the American Association for Cancer Research 44:66, 2003. e-Pub 2003.
Cristofanilli, M, Yamamura Y, Kau SW, Bevers TB, Strom SS, Patangan MG, Hsu LM, Krishnamurthy S, Hortobagyi GN. Thyroid hormones and breast cancer: primary hypothyroidism is associated with a reduced incidence of primary breast cancer. Proceedings of the American Association for Cancer Research 44:66, 2003. e-Pub 2003.
Sun, CC, Bodurka DC, Lu KH, Efron B, Andersen R, Bevers TB, Gershenson DM, Bast RC. Perceptions of OVCA risk and screening: differences between women with a history of breast cancer (WHxBr) and women with no history of breast cancer (WnoBr). Gynecol Oncol, 88:239, 2003. e-Pub 2003.
Boling, W, Carmack Taylor CL, Shinn EH, Dijk F, Zilstra R, Bevers TB, Basen-Engquist K. Breast cancer survivors and physical activity: Accuracy of self-report with surgeon general’s recommendations. Annals of Behavioral Medicine 24:S163, 2002. e-Pub 2002.
Boling, W, Carmack Taylor CL, Shinn EH, Dijk F, Zilstra R, Bevers TB, Basen-Engquist K. Breast cancer survivors and physical activity: Accuracy of self-report with surgeon general’s recommendations. Annals of Behavioral Medicine 24:S163, 2002. e-Pub 2002.
Wang, S, Bevers TB, Krishnamurthy S. Changes in cervicovaginal smears of women receiving tamoxifen for chemoprevention of breast cancer compared with those of women taking placebo. Mod Path 15:91A, 2002. e-Pub 2002.
Singletary, SE, Lieberman R, Binkley S, Atkinson EN, Sneige N, Sahin A, Bevers T, c S, Fornage B, Fritsche H, Hittelman W, Kelloff GJ, Lippman SM. Novel translational model for breast cancer chemoprevention study: presurgical intervention with tamoxifen and 4-HPR. Proceedings of the American Society of Clinical Oncology, 35th Annual Meeting, Atlanta, GA,:84a, 1999. e-Pub 1999.
Singletary, SE, Lieberman R, Binkley S, Atkinson EN, Sneige N, Sahin A, Bevers T, c S, Fornage B, Fritsche H, Hittelman W, Kelloff GJ, Lippman SM. Novel translational model for breast cancer chemoprevention study: presurgical intervention with tamoxifen and 4-HPR. Proceedings of the American Society of Clinical Oncology, 35th Annual Meeting, Atlanta, GA,:84a, 1999. e-Pub 1999.
Moseley T, Chung H, Patel M, Adrada B, Zylberman G, Bragner J, Arun B, Bevers TB, Rauch G. Comparative Performance of Molecular Breast Imaging (MBI) and Magnetic Resonance Imaging (MRI) for Annual Surveillance of Women at High Risk for Breast Cancer. EUSOBI.
Gilmore K, Nguyen L, Nguyen-Vu N, Johnson L, Amos C, Hartman R, Carpenter K, Roth M, Bevers TB, Bortolotti J, Foxhall L, Murphy T, Rodriguez MA. Using video-based and telementoring education program to support survivorship care in a primary care setting. International Cancer Education Conference.

Book Chapters

Nelson, AC, Bevers, TB. Survivorship Care of Gynecologic Cancer, 179-199, 2024.
Bevers, TB, El-Serag, H, Hanash, S, Thrift, AP, Tsai, K, Maresso, KC, Hawk, E. Screening and Early Detection. In: Abeloff's Clinical Oncology. Sixth. Elsevier, 375-398.e7, 2019.
Bevers T, Chapter 5 DS. Screening and Prevention Strategies. In: Handbook of Cancer Survivorship Care. Demos Medical/ Springer Publishing Company, 43-52, 2019.
Bevers T, Thomas PS. Clinical Management of the Patient at Increased or High Risk. In: The Breast: Comprehensive Management of Benign and Malignant Diseases. Fifth Edition. Elsevier Inc, 1004-1010, 2018.
Bevers, TB, Thomas, PS. Clinical Management of the Patient at Increased or High Risk. In: The Breast: Comprehensive Management of Benign and Malignant Diseases. Fifth. Elsevier, 1004-1010.e1, 2017.
Bevers, TB. Screening for Second Primary Cancers. Springer, 299-321, 2015.
Bevers T. Screening for Second Primary Cancer. In: Advances in Cancer Survivorship Management, MD Anderson Cancer Care Series. Springer, 299-321, 2015.
Bevers T, Brown PH, Maresso KC, Hawk ET. Cancer Prevention, Screening and Early Detection. In: Abeloff's Clinical Oncology. Fifth Edition. Elsevier, 322-59, 2014.
Bevers, TB, Brown, PH, Maresso, KC, Hawk, E. Cancer Prevention, Screening, and Early Detection. In: Abeloff's Clinical Oncology. Fifth, 322-359, 2013.
Bevers T. Breast Self-Examination: A Changing Paradigm. In: Advanced Therapy of Breast Disease, Third Edition. People's Medical Publishing House, 139-52, 2012.
Bevers, TB. Clinical Management of the Patient at Increased or High Risk. In: The Breast. Fourth. Elsevier, 1381-1392, 2009.
Bevers TB. Chapter 86: Clinical Management of the Patient at Increased or High Risk. In: The Breast: Comprehensive Management of Benign and Malignant Diseases, Fourth Edition. Saunders, 1381-92, 2009.
Bevers T, Bedrosian I. Chapter 72: Prevention: Prophylactic Mastectomy and Chemoprevention. In: Advanced Therapy for Surgical Oncology. BC Decker, Inc, 588-96, 2008.
Bevers TB. Primary Prevention and Screening for the Early Detection of Breast Cancer. In: Breast Cancer. M.D. Anderson Cancer Center. Springer-Verlag, 27-55, 2007.
Bevers T. Breast Self-examination. In: Advanced Therapy of Breast Disease, Second Edition. B.C. Decker, Inc.,, 193-201, 2004.
Coyne RL, Bevers T. Counseling about Risk Management. In: Handbook of Breast Cancer Risk Assessment: Evidence-based guidelines for evaluation, prevention, counseling, and management. Jones and Bartlett Publishers, 126-45, 2003.
Mizell V, Bevers T. Development of a Risk Assessment Clinic. In: Handbook of Breast Cancer Risk Assessment: Evidence-based guidelines for evaluation, prevention, counseling, and managemen. Jones and Bartlett Publishers, 41-54, 2003.
Lazzaro MV, Bevers T. Hormone Replacement Therapy. In: Handbook of Breast Cancer Risk Assessment: Evidence-based guidelines for evaluation, prevention, counseling, and management. Jones and Bartlett Publisher, 99-118, 2003.
Bevers T. Primary Prevention and Screening for the Early Detection of Breast Cancer. In: M.D. Anderson Cancer Care Series. Springer-Verlag, 21-54, 2001.
Bevers T. Diagnosis of Palpable Breast Masses. In: Advanced Therapy of Breast Disease, First Edition. B. C. Decker, Inc, 73-82, 2000.
Bevers T, Levin BL. Colorectal Cancer: Population Screening and Surveillance. In: Evidence Based Gastroenterology and Hepatology. BMJ Books, 230-240, 1999.

Books (edited and written)

Vogel VG, Bevers T, Editors. Handbook of breast cancer risk assessment: Evidence-based guidelines for evaluation, prevention, counseling, and management. Jones and Bartlett Publishers, 2003.

Letters to the Editor

Anderson BO, Bevers T, Carlson RW. Clinical Breast Examination and Breast Cancer Screening Guideline. JAMA 315: 1403-4, 2016.
Bevers T. Don't be confused by breast cancer studies. Houston Chronicle, 2015.
Hawk E, Bevers T, Volk R. Medicare patients need access to cancer tests. Houston Chronicle, 2014.
Mac Bride MB, Pruthi S, Bevers T. The evolution of breast self-examination to breast awareness. Breast J 18: 641-643, 2012.

Less

CV information above last modified January 02, 2026

Therese Bartholomew Bevers, MD, FAAFP

About Dr. Bevers

In the News

Alcohol and breast cancer risk: What to know

Can breastfeeding really lower your breast cancer risk?

5 little-known breast cancer facts

10 cancer symptoms women shouldn't ignore

Is talc in makeup safe?

6 breast cancer myths you shouldn’t believe

10 cancer symptoms men shouldn't ignore

Adoption and cancer risk: Should you get genetic testing?

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Cancer Prevention Center

Clinical Cancer Prevention Department

Cancer Prevention & Population Sciences Division

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop MD Anderson